

AHA/ACC CLINICAL PRACTICE GUIDELINE

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary

A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

WRITING COMMITTEE MEMBERS*

Steve R. Ommen, MD, FACC, FAHA, Chair†
Seema Mital, MD, FACC, FAHA, FRCPC, Vice Chair†
Michael A. Burke, MD†
Sharlene M. Day, MD†
Anita Deswal, MD, MPH, FACC, FAHA‡§
Perry Elliott, MD, FRCPC, FACC†
Lauren L. Evanovich, PhD†
Judy Hung, MD, FACC‖
José A. Joglar, MD, FACC, FAHA†
Paul Kantor, MBBCh, MSc, FRCPC†
Carey Kimmelstiel, MD, FACC, FSCAI†
Michelle Kittleson, MD, PhD, FACC†
Mark S. Link, MD, FACC¶
Martin S. Maron, MD#
Matthew W. Martinez, MD, FACC†
Christina Y. Miyake, MD, MS†
Hartzell V. Schaff, MD, FACC**
Christopher Semsarian, MBBS, PhD, MPH, FAHA†
Paul Sorajja, MD, FACC, FAHA, FSCAI††

Developed in collaboration with and endorsed by the American Association for Thoracic Surgery, American Society of Echocardiography, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society for Cardiovascular Magnetic Resonance

Endorsed by The Pediatric & Congenital Electrophysiology Society

ACC/AHA Joint Committee Members, see page e549

Key Words: AHA Scientific Statements ■ guidelines ■ hypertrophic cardiomyopathy ■ sarcomeric genes ■ shared decision-making ■ echocardiography ■ cardiovascular magnetic resonance ■ exercise stress testing ■ left ventricular outflow tract obstruction ■ systolic dysfunction ■ diastolic dysfunction ■ genetics ■ family screening ■ sudden cardiac death ■ ventricular arrhythmias ■ atrial fibrillation ■ rhythm monitoring ■ risk stratification ■ implantable cardioverter defibrillator ■ septal reduction therapy ■ surgical myectomy ■ septal alcohol ablation ■ physical activity ■ pregnancy ■ occupation

*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. †ACC/AHA Representative. ‡ACC/AHA Joint Committee on Clinical Practice Guidelines Liaison. §HFSA Representative. ¶ASE Representative. ¶HRS Representative. #SCMR Representative. **AATS Representative. ††SCAI Representative.

The American Heart Association requests that this document be cited as follows: Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2020;142:e533–e557. doi: 10.1161/CIR.0000000000000938

© 2020 by the American Heart Association, Inc., and the American College of Cardiology Foundation.

<https://www.ahajournals.org/journal/circ>

AIM: This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patients as well as supporting documentation to encourage their use.

METHODS: A comprehensive literature search was conducted from January 1, 2010, to April 30, 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Collaboration, Agency for Healthcare Research and Quality reports, and other relevant databases.

STRUCTURE: Many recommendations from the earlier hypertrophic cardiomyopathy guidelines have been updated with new evidence or a better understanding of earlier evidence. This summary operationalizes the recommendations from the full guideline and presents a combination of diagnostic work-up, genetic and family screening, risk stratification approaches, lifestyle modifications, surgical and catheter interventions, and medications that constitute components of guideline directed medical therapy. For both guideline-directed medical therapy and other recommended drug treatment regimens, the reader is advised to follow dosing, contraindications and drug-drug interactions based on product insert materials.

TABLE OF CONTENTS

Top 10 Take-Home Messages–2020 AHA/ACC Guideline For the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy e534

Purpose of the Executive Summary e536

Document Review and Approval e537

Class of Recommendation and Level of Evidence e537

1. Shared Decision-Making e537

2. Multidisciplinary HCM Centers. e537

3. Diagnosis, Initial Evaluation, and Follow-up e537

3.1. Clinical Diagnosis e537

3.2. Echocardiography e539

3.3. Cardiovascular Magnetic Resonance Imaging e539

3.4. Cardiac Computed Tomography e539

3.5. Heart Rhythm Assessment e540

3.6. Angiography and Invasive Hemodynamic Assessment e540

3.7. Exercise Stress Testing e540

3.8. Genetics and Family Screening. e540

3.9. Genotype-Positive, Phenotype-Negative. e542

4. SCD Risk Assessment and Prevention. e542

4.1. SCD Risk Assessment. e542

4.2. Patient Selection for ICD Placement. e542

4.3. Device Selection Considerations. e543

5. Management of HCM e544

5.1. Management of Symptomatic Patients With Obstructive HCM e544

5.1.1. Pharmacologic Management of Symptomatic Patients With Obstructive HCM e544

5.1.2. Invasive Treatment of Symptomatic Patients With Obstructive HCM. e544

5.2. Management of Patients With Nonobstructive HCM With Preserved EF. e546

5.3. Management of Patients With HCM and Atrial Fibrillation e546

5.4. Management of Patients With HCM and Ventricular Arrhythmias e546

5.5. Management of Patients With HCM and Advanced HF e546

6. Lifestyle Considerations for Patients With HCM e548

6.1. Sports and Activity. e548

6.2. Occupation e548

6.3. Pregnancy e549

6.4. Comorbidities e549

References. e550

TOP 10 TAKE-HOME MESSAGES–2020 AHA/ACC GUIDELINE FOR THE DIAGNOSIS AND TREATMENT OF PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

1. Shared decision-making, a dialogue between patients and their care team that includes full disclosure of all testing and treatment options, discussion of the risks and benefits of those options and, importantly, engagement of the patient to express their own goals, is particularly relevant in the management of conditions such as hypertrophic cardiomyopathy (HCM).
2. Although the primary cardiology team can initiate evaluation, treatment, and longitudinal care, referral to multidisciplinary HCM centers with graduated levels of expertise can be important to optimizing care for patients with HCM. Challenging treatment decisions—where reasonable alternatives exist, where the strength of recommendation is weak (eg, any Class 2b decision)

Downloaded from <http://ahajournals.org> by on April 20, 2024

or is particularly nuanced, and for invasive procedures that are specific to patients with HCM—represent crucial opportunities to refer patients to these HCM centers.

3. Counseling patients with HCM regarding the potential for genetic transmission of HCM is one of the cornerstones of care. Screening first-degree family members of patients with HCM, using either genetic testing or an imaging/electrocardiographic surveillance protocol, can begin at any age and can be influenced by specifics of the patient/family history and family preference. As screening recommendations for family members hinge on the pathogenicity of any detected variants, the reported pathogenicity should be reconfirmed every 2 to 3 years.
4. Optimal care for patients with HCM requires cardiac imaging to confirm the diagnosis, characterize the pathophysiology for the individual, and identify risk markers that may inform decisions regarding interventions for left ventricular outflow tract obstruction and sudden cardiac death (SCD) prevention. Echocardiography continues to be the foundational imaging modality for patients with HCM. Cardiovascular magnetic resonance imaging will also be helpful in many patients, especially those in whom there is diagnostic uncertainty, poor echocardiographic imaging windows, or where uncertainty persists regarding decisions around implantable cardioverter-defibrillator (ICD) placement.
5. Assessment of an individual patient's risk for SCD continues to evolve as new markers emerge (eg, apical aneurysm, decreased left ventricular systolic function, and extensive gadolinium enhancement). In addition to a full accounting of an individual's risk markers, communication with patients regarding not just the presence of risk markers but also the magnitude of their individualized risk is key. This enables the informed patient to fully participate in the decision-making regarding ICD placement, which incorporates their own level of risk tolerance and treatment goals.
6. The risk factors for SCD in children with HCM carry different weights than those observed in adult patients; they vary with age and must account for different body sizes. Coupled with the complexity of placing ICDs in young patients with anticipated growth and a higher risk of device complications, the threshold for ICD implantation in children often differs from adults. These differences are best addressed at primary or comprehensive HCM centers with expertise in children with HCM.
7. Septal reduction therapies (surgical septal myectomy and alcohol septal ablation), when performed by experienced HCM teams at dedicated centers, continue to improve in safety and efficacy such that earlier intervention may be possible in select patients with drug-refractory or severe outflow tract obstruction causing signs of cardiac decompensation. Given the data on the significantly improved outcomes at comprehensive HCM centers, these decisions represent an optimal referral opportunity.
8. Patients with HCM and persistent or paroxysmal atrial fibrillation have a sufficiently increased risk of stroke such that oral anticoagulation with direct oral anticoagulants (or alternatively warfarin) should be considered the default treatment option independent of the CHA₂DS₂-VASc score. As rapid atrial fibrillation is often poorly tolerated in patients with HCM, maintenance of sinus rhythm and rate control are key pursuits in successful treatment.
9. Heart failure symptoms in patients with HCM, in the absence of left ventricular outflow tract obstruction, should be treated similarly to other patients with heart failure symptoms, including consideration of advanced treatment options (eg, cardiac resynchronization therapy, left ventricular assist device, transplantation). In patients with HCM, an ejection fraction <50% connotes significantly impaired systolic function and identifies individuals with poor prognosis and who are at increased risk for SCD.
10. Increasingly, data affirm that the beneficial effects of exercise on general health can be extended to patients with HCM. Healthy recreational exercise (moderate intensity) has not been associated with increased risk of ventricular arrhythmia events in recent studies. Whether an individual patient with HCM wishes to pursue more rigorous exercise/training is dependent on a comprehensive shared discussion between that patient and their expert HCM care team regarding the potential risks of that level of training/participation but with the understanding that exercise-related risk cannot be individualized for a given patient.

Table 2. ACC/AHA Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care (Updated May 2019)*

| CLASS (STRENGTH) OF RECOMMENDATION | LEVEL (QUALITY) OF EVIDENCE‡ |
|---|---|
| CLASS 1 (STRONG) Benefit >>> Risk Suggested phrases for writing recommendations: <ul style="list-style-type: none"> • Is recommended • Is indicated/useful/effective/beneficial • Should be performed/administered/other • Comparative-Effectiveness Phrases†: <ul style="list-style-type: none"> – Treatment/strategy A is recommended/indicated in preference to treatment B – Treatment A should be chosen over treatment B | LEVEL A <ul style="list-style-type: none"> • High-quality evidence‡ from more than 1 RCT • Meta-analyses of high-quality RCTs • One or more RCTs corroborated by high-quality registry studies |
| CLASS 2a (MODERATE) Benefit >> Risk Suggested phrases for writing recommendations: <ul style="list-style-type: none"> • Is reasonable • Can be useful/effective/beneficial • Comparative-Effectiveness Phrases†: <ul style="list-style-type: none"> – Treatment/strategy A is probably recommended/indicated in preference to treatment B – It is reasonable to choose treatment A over treatment B | LEVEL B-R (Randomized) <ul style="list-style-type: none"> • Moderate-quality evidence‡ from 1 or more RCTs • Meta-analyses of moderate-quality RCTs |
| CLASS 2b (WEAK) Benefit ≥ Risk Suggested phrases for writing recommendations: <ul style="list-style-type: none"> • May/might be reasonable • May/might be considered • Usefulness/effectiveness is unknown/unclear/uncertain or not well-established | LEVEL B-NR (Nonrandomized) <ul style="list-style-type: none"> • Moderate-quality evidence‡ from 1 or more well-designed, well-executed nonrandomized studies, observational studies, or registry studies • Meta-analyses of such studies |
| CLASS 3: No Benefit (MODERATE) Benefit = Risk (Generally, LOE A or B use only) Suggested phrases for writing recommendations: <ul style="list-style-type: none"> • Is not recommended • Is not indicated/useful/effective/beneficial • Should not be performed/administered/other | LEVEL C-LD (Limited Data) <ul style="list-style-type: none"> • Randomized or nonrandomized observational or registry studies with limitations of design or execution • Meta-analyses of such studies • Physiological or mechanistic studies in human subjects |
| Class 3: Harm (STRONG) Risk > Benefit Suggested phrases for writing recommendations: <ul style="list-style-type: none"> • Potentially harmful • Causes harm • Associated with excess morbidity/mortality • Should not be performed/administered/other | LEVEL C-EO (Expert Opinion) <ul style="list-style-type: none"> • Consensus of expert opinion based on clinical experience |

COR and LOE are determined independently (any COR may be paired with any LOE).
 A recommendation with LOE C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although RCTs are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
 * The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information).
 † For comparative-effectiveness recommendations (COR 1 and 2a; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.
 ‡ The method of assessing quality is evolving, including the application of standardized, widely-used, and preferably validated evidence grading tools; and for systematic reviews, the incorporation of an Evidence Review Committee.
 COR indicates Class of Recommendation; EO, expert opinion; LD, limited data; LOE, Level of Evidence; NR, nonrandomized; R, randomized; and RCT, randomized controlled trial.

PURPOSE OF THE EXECUTIVE SUMMARY

This executive summary of the American Heart Association (AHA)/American College of Cardiology (ACC) hypertrophic cardiomyopathy (HCM) clinical practice guideline¹ provides a synopsis with algorithms to guide clinicians in the screening, diagnosis, and management of HCM in pediatric and adult patients.

The full guideline¹ recommends a combination of lifestyle modifications, medications, and surgical/catheter interventions that constitute components of

guideline-directed medical therapy. For both guideline-directed medical therapy and other recommended drug treatment regimens, the reader is advised to follow dosing, contraindications and drug-drug interactions based on product insert materials.

The full guideline¹ replaces the 2011 guideline.² Some recommendations from the earlier HCM guidelines have been updated by new evidence or a better understanding of earlier evidence, whereas others that were outdated, irrelevant, or overlapping were deleted or modified. The overall goal was to provide the clinician with concise, evidence-based, contemporary

recommendations with supporting data to encourage their use. Sections were divided into the following: 1) diagnosis and follow-up (including genetic and family screening), 2) sudden cardiac death risk assessment and prevention, 3) medical, surgical, and catheter interventions in the management of HCM (obstructive HCM, nonobstructive HCM, atrial fibrillation, ventricular arrhythmias, advanced heart failure), and 4) lifestyle considerations (sports/activity, occupation, pregnancy, comorbidities). There was a strong emphasis on shared decision-making that accounts for patient choices, and the importance of skilled operators and experienced centers that can guide complex decision-making and perform complex procedures with superior outcomes.

The full guideline¹ contains Table 1 and Table 8, which are not cited in this executive summary. The 5 figures included in this executive summary are also included in the full guideline.¹

DOCUMENT REVIEW AND APPROVAL

The guideline was reviewed by 2 official reviewers each nominated by the ACC and AHA, 1 reviewer each from the American Association for Thoracic Surgery, American Society of Echocardiography, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, the Society for Cardiovascular Magnetic Resonance, and 26 individual content reviewers. Information about the authors' relevant relationships with industry and other entities is available as Appendix 1 in the full guideline.¹ Information about the reviewers' comprehensive relationships with industry and other entities was distributed to the writing committee and is published as Appendix 2 in the full guideline.¹

CLASS OF RECOMMENDATION AND LEVEL OF EVIDENCE

The Class of Recommendation (COR) indicates the strength of recommendation, encompassing the estimated magnitude and certainty of benefit in proportion to risk. The Level of Evidence (LOE) rates the quality of scientific evidence supporting the intervention on the basis of the type, quantity, and consistency of data from clinical trials and other sources (Table 2).³

1. SHARED DECISION-MAKING

| Recommendation for Shared Decision-Making Referenced studies that support the recommendation are summarized in Online Data Supplement 1. | | |
|---|------|--|
| COR | LOE | Recommendation |
| 1 | B-NR | 1. For patients with HCM or at risk for HCM, shared decision-making is recommended in developing a plan of care (including but not limited to decisions regarding genetic evaluation, activity, lifestyle, and therapy choices) that includes a full disclosure of the risks, benefits, and anticipated outcomes of all options, as well the opportunity for the patient to express their goals and concerns. ⁴⁻⁹ |

2. MULTIDISCIPLINARY HCM CENTERS

Tables in this section are located in the full guideline.¹

| Recommendations for Multidisciplinary HCM Centers | | |
|---|------|---|
| COR | LOE | Recommendations |
| 1 | C-LD | 1. In patients with HCM in whom septal reduction therapy (SRT) is indicated, the procedure should be performed at experienced centers (comprehensive or primary HCM centers) with demonstrated excellence in clinical outcomes for these procedures ¹⁰⁻¹² (Table 3 and Table 4). |
| 2a | C-LD | 2. In patients with HCM, consultation with or referral to a comprehensive or primary HCM center is reasonable to aid in complex disease-related management decisions ¹³⁻²² (Table 3). |

3. DIAGNOSIS, INITIAL EVALUATION, AND FOLLOW-UP

3.1. Clinical Diagnosis

Tables in this section are located in the full guideline.¹ Figure 1 presents a recommended evaluation and testing for HCM.

| Recommendation for Diagnosis, Initial Evaluation, and Follow-up Referenced studies that support the recommendation are summarized in Online Data Supplement 2. | | |
|---|------|--|
| COR | LOE | Recommendation |
| 1 | B-NR | 1. In patients with suspected HCM, comprehensive physical examination and complete medical and 3-generation family history is recommended as part of the initial diagnostic assessment ²³⁻²⁸ (Table 5 and Table 6). |




Figure 1. Recommended evaluation and testing for HCM.

Colors correspond to the Class of Recommendation in Table 2. *The interval may be extended, particularly in adult patients who remain stable after multiple evaluations. CMR indicates cardiovascular magnetic resonance; CPET, cardiopulmonary exercise test; ECG, electrocardiography/electrocardiogram; HCM, hypertrophic cardiomyopathy; HF, heart failure; ICD, implantable cardioverter-defibrillator; LVOTO, left ventricular outflow tract obstruction; P/LP, pathogenic or likely pathogenic variant; SCD, sudden cardiac death; and VUS, variant of unknown significance.

Downloaded from <http://ahajournals.org> by on April 20, 2024

3.2. Echocardiography

| Recommendations for Echocardiography Referenced studies that support the recommendations are summarized in Online Data Supplement 3. | | |
|---|---------------|---|
| COR | LOE | Recommendations |
| 1 | B-NR | 1. In patients with suspected HCM, a transthoracic echocardiogram (TTE) is recommended in the initial evaluation. ²⁹⁻³⁴ |
| 1 | B-NR children | 2. In patients with HCM with no change in clinical status or events, repeat TTE is recommended every 1 to 2 years to assess the degree of myocardial hypertrophy, dynamic left ventricular outflow tract obstruction (LVOTO), mitral regurgitation, and myocardial function ³⁵⁻⁴² (Figure 1). |
| 1 | C-LD adults | |
| 1 | B-NR | 3. For patients with HCM who experience a change in clinical status or a new clinical event, repeat TTE is recommended. ^{35,38,43-46} |
| 1 | B-NR | 4. For patients with HCM and resting left ventricular outflow tract gradient <50 mm Hg, a TTE with provocative maneuvers is recommended. ⁴⁷⁻⁵⁰ |
| 1 | B-NR | 5. For symptomatic patients with HCM who do not have a resting or provocative outflow tract gradient ≥50 mm Hg on TTE, exercise TTE is recommended for the detection and quantification of dynamic LVOTO. ⁴⁹⁻⁵⁴ |
| 1 | B-NR | 6. For patients with HCM undergoing surgical septal myectomy, intraoperative transesophageal echocardiogram (TEE) is recommended to assess mitral valve anatomy and function and adequacy of septal myectomy. ⁵⁵⁻⁵⁸ |
| 1 | B-NR | 7. For patients with HCM undergoing alcohol septal ablation, TTE or intraoperative TEE with intracoronary ultrasound-enhancing contrast injection of the candidate's septal perforator(s) is recommended. ^{31,59-63} |
| 1 | B-NR | 8. For patients with HCM who have undergone SRT, TTE within 3 to 6 months after the procedure is recommended to evaluate the procedural results. ^{17,64-66} |
| 1 | B-NR | 9. Screening: In first-degree relatives of patients with HCM, a TTE is recommended as part of initial family screening and periodic follow-up ^{31-33,35,36,61} (Figure 1, Table 6). |
| 1 | B-NR | 10. Screening: In individuals who are genotype-positive or phenotype-negative, serial echocardiography is recommended at periodic intervals depending on age (1 to 2 years in children and adolescents, 3 to 5 years in adults) and change in clinical status (Table 6; Figure 1). ^{28,67,69-71} |
| 2a | C-LD | 11. For patients with HCM, TEE can be useful if TTE is inconclusive in clinical decision-making regarding medical therapy, and in situations such as planning for myectomy, exclusion of subaortic membrane or mitral regurgitation secondary to structural abnormalities of the mitral valve apparatus, or in the assessment of the feasibility of alcohol septal ablation. ⁵⁵⁻⁵⁸ |
| 2a | B-NR | 12. For patients with HCM in whom the diagnoses of apical HCM, apical aneurysm, or atypical patterns of hypertrophy is inconclusive on TTE, the use of an intravenous ultrasound-enhancing agent is reasonable particularly if other imaging modalities such as cardiovascular magnetic resonance (CMR) are not readily available or contraindicated. ^{72,73} |

| Recommendations for Echocardiography (Continued) | | |
|--|------|---|
| COR | LOE | Recommendations |
| 2a | C-LD | 13. For asymptomatic patients with HCM who do not have a resting or provocative outflow tract gradient ≥50 mm Hg on standard TTE, exercise TTE is reasonable for the detection and quantification of dynamic LVOTO. ^{43,48,49,51-54} |

3.3. Cardiovascular Magnetic Resonance Imaging

| Recommendations for CMR Imaging Referenced studies that support the recommendations are summarized in Online Data Supplement 4. | | |
|--|------|--|
| COR | LOE | Recommendations |
| 1 | B-NR | 1. For patients suspected to have HCM in whom echocardiography is inconclusive, CMR imaging is indicated for diagnostic clarification. ⁷⁴⁻⁸⁰ |
| 1 | B-NR | 2. For patients with left ventricular hypertrophy in whom there is a suspicion of alternative diagnoses including infiltrative or storage disease as well as athlete's heart, CMR imaging is useful ⁷⁴⁻⁸⁰ (Figure 1). |
| 1 | B-NR | 3. For patients with HCM who are not otherwise identified as high risk for sudden cardiac death (SCD), or in whom a decision to proceed with implantable cardioverter-defibrillator (ICD) remains uncertain after clinical assessment that includes personal/family history, echocardiography, and ambulatory electrocardiographic monitoring, CMR imaging is beneficial to assess for maximum left ventricular (LV) wall thickness, ejection fraction (EF), LV apical aneurysm, and extent of myocardial fibrosis with late gadolinium enhancement. ^{38,74-87} |
| 1 | B-NR | 4. For patients with obstructive HCM in whom the anatomic mechanism of obstruction is inconclusive on echocardiography, CMR imaging is indicated to inform the selection and planning of SRT. ⁸⁸⁻⁹² |
| 2b | C-EO | 5. For patients with HCM, repeat contrast-enhanced CMR imaging on a periodic basis (every 3 to 5 years) for the purpose of SCD risk stratification may be considered to evaluate changes in late gadolinium enhancement and other morphologic changes, including EF, development of apical aneurysm, or LV wall thickness (Figure 1, Table 7). |

3.4. Cardiac Computed Tomography

| Recommendation for Cardiac Computed Tomography (CT) | | |
|---|------|---|
| COR | LOE | Recommendation |
| 2b | C-LD | 1. In adult patients with suspected HCM, cardiac CT may be considered for diagnosis if the echocardiogram is not diagnostic and CMR imaging is unavailable. ^{34,93,94} |

Downloaded from http://ahajournals.org by on April 20, 2024

3.5. Heart Rhythm Assessment

| Recommendations for Heart Rhythm Assessment Referenced studies that support the recommendations are summarized in Online Data Supplement 5. | | |
|--|------|---|
| COR | LOE | Recommendations |
| 1 | B-NR | 1. In patients with HCM, a 12-lead ECG is recommended in the initial evaluation and as part of periodic follow-up (every 1 to 2 years) ⁹⁵⁻⁹⁷ (Figure 1, Table 6). |
| 1 | B-NR | 2. In patients with HCM, 24- to 48-hour ambulatory electrocardiographic monitoring is recommended in the initial evaluation and as part of periodic follow-up (every 1 to 2 years) to identify patients who are at risk for SCD and guide management of arrhythmias (Figure 1). ⁹⁸⁻¹⁰⁰ |
| 1 | B-NR | 3. In patients with HCM who develop palpitations or lightheadedness, extended (>24 hours) electrocardiographic monitoring or event recording is recommended, which should not be considered diagnostic unless patients have had symptoms while being monitored. ¹⁰¹ |
| 1 | B-NR | 4. In first-degree relatives of patients with HCM, a 12-lead ECG is recommended as a component of the screening algorithm ⁹⁵⁻⁹⁷ (Figure 1, Table 6). |
| 2a | B-NR | 5. In patients with HCM who have additional risk factors for atrial fibrillation (AF), such as left atrial dilatation, advanced age, and New York Heart Association (NYHA) class III to class IV heart failure (HF), and who are eligible for anticoagulation, extended ambulatory monitoring is reasonable to screen for AF as part of initial evaluation and periodic follow-up (every 1 to 2 years) ¹⁰²⁻¹⁰⁶ (Figure 1). |
| 2b | B-NR | 6. In adult patients with HCM without risk factors for AF and who are eligible for anticoagulation, extended ambulatory monitoring may be considered to assess for asymptomatic paroxysmal AF as part of initial evaluation and periodic follow-up (every 1 to 2 years). ¹⁰²⁻¹⁰⁶ |

3.6. Angiography and Invasive Hemodynamic Assessment

| Recommendations for Angiography and Invasive Hemodynamic Assessment Referenced studies that support the recommendations are summarized in Online Data Supplement 6. | | |
|--|------|--|
| COR | LOE | Recommendations |
| 1 | B-NR | 1. For patients with HCM who are candidates for SRT and for whom there is uncertainty regarding the presence or severity of LVOTO on noninvasive imaging studies, invasive hemodynamic assessment with cardiac catheterization is recommended. ^{45,107-109} |
| 1 | B-NR | 2. In patients with HCM with symptoms or evidence of myocardial ischemia, coronary angiography (CT or invasive) is recommended. ¹¹⁰ |
| 1 | B-NR | 3. In patients with HCM who are at risk of coronary atherosclerosis, coronary angiography (CT or invasive) is recommended before surgical myectomy. ¹¹¹ |

3.7. Exercise Stress Testing

| Recommendations for Exercise Stress Testing Referenced studies that support the recommendations are summarized in Online Data Supplement 7. | | |
|--|------|--|
| COR | LOE | Recommendations |
| 1 | B-NR | 1. For symptomatic patients with HCM who do not have resting or provokable outflow tract gradient ≥ 50 mm Hg on TTE, exercise TTE is recommended for the detection and quantification of dynamic LVOTO. ^{50,112} |
| 1 | B-NR | 2. In patients with nonobstructive HCM and advanced HF (NYHA functional class III to class IV despite guideline-directed management and therapy), cardiopulmonary exercise stress testing should be performed to quantify the degree of functional limitation and aid in selection of patients for heart transplantation or mechanical circulatory support. ^{113,114} |
| 2a | B-NR | 3. In patients with HCM, exercise stress testing is reasonable to determine functional capacity and to provide prognostic information as part of initial evaluation. ^{113,114} |
| 2a | C-LD | 4. For asymptomatic patients with HCM who do not have a resting or provokable outflow tract gradient ≥ 50 mm Hg on standard TTE, exercise TTE is reasonable for the detection and quantification of dynamic LVOTO. ^{49,51-54,115} |
| 2b | C-EO | 5. In patients with obstructive HCM, who are being considered for SRT, and in whom functional capacity or symptom status is uncertain, exercise stress testing may be reasonable (Figure 1). |
| 2b | C-EO | 6. In patients with HCM in whom functional capacity or symptom status is uncertain, exercise stress testing may be considered every 2 to 3 years (Figure 1). |

3.8. Genetics and Family Screening

Figure 2 presents a genetic testing process for HCM.

| Recommendations for Genetics and Family Screening Referenced studies that support the recommendations are summarized in Online Data Supplements 8 and 9. | | |
|---|------|--|
| COR | LOE | Recommendations |
| 1 | B-NR | 1. In patients with HCM, evaluation of familial inheritance, including a 3-generation family history, is recommended as part of the initial assessment. ^{23,25-28,117,118} |
| 1 | B-NR | 2. In patients with HCM, genetic testing is beneficial to elucidate the genetic basis to facilitate the identification of family members at risk for developing HCM (cascade testing). ¹¹⁹⁻¹²² |
| 1 | B-NR | 3. In patients with an atypical clinical presentation of HCM or when another genetic condition is suspected to be the cause, a work-up including genetic testing for HCM and other genetic causes of unexplained cardiac hypertrophy ("HCM phenocopies") is recommended. ¹²³⁻¹²⁵ |
| 1 | B-NR | 4. In patients with HCM who choose to undergo genetic testing, pre- and posttest genetic counseling by an expert in the genetics of cardiovascular disease is recommended so that risks, benefits, results, and their clinical significance can be reviewed and discussed with the patient in a shared decision-making process. ^{23-25,117} |
| 1 | B-NR | 5. When performing genetic testing in an HCM proband, the initial tier of genes tested should include genes with strong evidence to be disease-causing in HCM.* ^{119,122,127,128} |

| Recommendations for Genetics and Family Screening (Continued) | | |
|---|------|--|
| COR | LOE | Recommendations |
| 1 | B-NR | 6. In first-degree relatives of patients with HCM, both clinical screening (ECG and 2D echocardiogram) and cascade genetic testing (when a pathogenic/likely pathogenic variant has been identified in the proband) should be offered. ^{23,67,123,130-132} |
| 1 | B-NR | 7. In families where a sudden unexplained death has occurred with a postmortem diagnosis of HCM, postmortem genetic testing is beneficial to facilitate cascade genetic testing and clinical screening in first-degree relatives. ^{133,134} |
| 1 | B-NR | 8. In patients with HCM who have undergone genetic testing, serial reevaluation of the variant(s) identified is recommended to assess for variant reclassification, which may impact diagnosis and cascade genetic testing in family members. ¹³⁵⁻¹³⁷ (Figure 1 and Figure 2) |
| 1 | B-NR | 9. In affected families with HCM, preconception and prenatal reproductive and genetic counseling should be offered. ^{23-25,117} |

| Recommendations for Genetics and Family Screening (Continued) | | |
|---|------|--|
| COR | LOE | Recommendations |
| 2b | B-NR | 10. In patients with HCM, the usefulness of genetic testing in the assessment of risk of SCD is uncertain. ^{121,137-139} |
| 2b | B-NR | 11. In patients with HCM who harbor a variant of uncertain significance, the usefulness of clinical genetic testing of phenotype-negative relatives for the purpose of variant reclassification is uncertain. ^{28,70,118,119} |
| 3: No benefit | B-NR | 12. For patients with HCM who have undergone genetic testing and were found to have no pathogenic variants (ie, harbor only benign/likely benign variants), cascade genetic testing of the family is not useful. ¹¹⁸⁻¹²¹ |
| 3: No benefit | B-NR | 13. Ongoing clinical screening is not indicated in genotype-negative relatives in families with genotype-positive HCM, unless the disease-causing variant is downgraded to variant of uncertain significance, likely benign, or benign variant during follow-up. ^{15,135,140,142,143} |

*Strong evidence HCM genes include, at the time of this publication, MYH7, MYBPC3, TNNI3, TNNT2, TPM1, MYL2, MYL3, and ACTC1.




Figure 2. Genetic testing process in HCM.

Colors correspond to the Class of Recommendation in Table 2. HCM indicates hypertrophic cardiomyopathy; LB/B, likely benign/benign; LP/P, likely pathogenic or pathogenic; and VUS, variant of unknown significance.

3.9. Genotype-Positive, Phenotype-Negative

| Recommendations for Individuals Who Are Genotype-Positive, Phenotype-Negative Referenced studies that support the recommendations are summarized in Online Data Supplement 10. | | |
|---|------|--|
| COR | LOE | Recommendations |
| 1 | B-NR | 1. In individuals who are genotype-positive, phenotype-negative for HCM, serial clinical assessment, electrocardiography, and cardiac imaging are recommended at periodic intervals depending on age (every 1 to 2 years in children and adolescents, and every 3 to 5 years in adults) and change in clinical status. ^{28,67,69-71} (Figure 1 and Figure 2, Table 6) |
| 2a | C-LD | 2. In individuals who are genotype-positive, phenotype-negative for HCM, participation in competitive athletics of any intensity is reasonable. ¹³² |
| 3: No benefit | B-NR | 3. In individuals who are genotype-positive, phenotype-negative for HCM, ICD is not recommended for primary prevention. ^{28,69-71,132,145} |

4. SCD RISK ASSESSMENT AND PREVENTION

4.1. SCD Risk Assessment

| Recommendations for SCD Risk Assessment Referenced studies that support the recommendations are summarized in Online Data Supplement 11. | | |
|---|------|--|
| COR | LOE | Recommendations |
| 1 | B-NR | 1. In patients with HCM, a comprehensive, systematic noninvasive SCD risk assessment at initial evaluation and every 1 to 2 years thereafter is recommended and should include evaluation of these risk factors ^{38,78,79,81,83-87,99,146-160} (Figure 1 and Figure 3, Table 7): a. Personal history of cardiac arrest or sustained ventricular arrhythmias b. Personal history of syncope suspected by clinical history to be arrhythmic c. Family history in close relative of premature HCM-related sudden death, cardiac arrest, or sustained ventricular arrhythmias d. Maximal LV wall thickness, EF, LV apical aneurysm e. Nonsustained ventricular tachycardia episodes on continuous ambulatory electrocardiographic monitoring |
| 1 | B-NR | 2. For patients with HCM who are not otherwise identified as high risk for SCD, or in whom a decision to proceed with ICD placement remains uncertain after clinical assessment that includes personal/family history, echocardiography, and ambulatory electrocardiographic monitoring, CMR imaging is beneficial to assess for maximum LV wall thickness, EF, LV apical aneurysm, and extent of myocardial fibrosis with late gadolinium enhancement ^{78,79,81,83-86,146,155} (Table 7). |
| 2a | B-NR | 3. For patients who are ≥16 years of age with HCM, it is reasonable to obtain echocardiography-derived left atrial diameter and maximal left ventricular outflow tract gradient to aid in calculating an estimated 5-year sudden death risk that may be useful during shared decision-making for ICD placement ^{147,157} (Table 7). |

4.2. Patient Selection for ICD Placement

| Recommendations for ICD Placement in High-Risk Patients With HCM Referenced studies that support the recommendations are summarized in Online Data Supplement 12. | | |
|--|------|--|
| COR | LOE | Recommendations |
| 1 | C-EO | 1. In patients with HCM, application of individual clinical judgment is recommended when assessing the prognostic strength of conventional risk marker(s) within the clinical profile of the individual patient, as well as a thorough and balanced discussion of the evidence, benefits, and estimated risks to engage the fully informed patient's active participation in ICD decision-making. ^{13,146,161-163} |
| 1 | B-NR | 2. For patients with HCM, and previous documented cardiac arrest or sustained ventricular tachycardia, ICD placement is recommended ^{146,148,161-163} (Figure 3, Table 7). |
| 2a | B-NR | 3. For adult patients with HCM with ≥1 major risk factors for SCD, it is reasonable to offer an ICD. These major risk factors include ^{38,81,87,99,146,149-157,159-161} (Figure 3, Table 7): a. Sudden death judged definitively or likely attributable to HCM in ≥1 first-degree or close relatives who are ≤50 years of age; b. Massive left ventricular hypertrophy ≥30 mm in any left ventricular segment; c. ≥1 Recent episodes of syncope suspected by clinical history to be arrhythmic (ie, unlikely to be of neurocardiogenic [vasovagal] etiology, or related to LVOTO); d. LV apical aneurysm, independent of size; e. LV systolic dysfunction (EF <50%). |
| 2a | B-NR | 4. For children with HCM who have ≥1 conventional risk factors, including unexplained syncope, massive left ventricular hypertrophy, nonsustained ventricular tachycardia, or family history of early HCM-related SCD, ICD placement is reasonable after considering the relatively high complication rates of long-term ICD placement in younger patients ¹⁶⁴⁻¹⁷¹ (Figure 3, Table 7). |
| 2a | B-NR | 5. For patients ≥16 years of age with HCM and with ≥1 major SCD risk factors, discussion of the estimated 5-year sudden death risk and mortality rates can be useful during the shared decision-making process for ICD placement ^{157,161} (Figure 3, Table 7). |
| 2b | B-NR | 6. In select adult patients with HCM and without major SCD risk factors after clinical assessment, or in whom the decision to proceed with ICD placement remains otherwise uncertain, ICD may be considered in patients with extensive late gadolinium enhancement by contrast-enhanced CMR imaging or nonsustained ventricular tachycardia present on ambulatory monitoring ^{84-86,99,146,157,161,170} (Figure 3, Table 7). |
| 2b | C-LD | 7. In select pediatric patients with HCM in whom risk stratification is otherwise less certain, it may be useful to consider additional factors such as extensive late gadolinium enhancement on contrast-enhanced CMR imaging and systolic dysfunction in risk stratification ^{172,173} (Figure 3, Table 7). |
| 3: Harm | B-NR | 8. In patients with HCM without risk factors, ICD placement should not be performed. ^{85,146} |
| 3: Harm | B-NR | 9. In patients with HCM, ICD placement for the sole purpose of participation in competitive athletics should not be performed. ¹⁷⁴ |

Table 7. Established Clinical Risk Factors for HCM Sudden Death Risk Stratification

| | |
|---|---|
| Family history of sudden death from HCM | Sudden death judged definitively or likely attributable to HCM in ≥1 first-degree or close relatives who are ≤50 y of age. Close relatives would generally be second-degree relatives; however, multiple SCDs in tertiary relatives should also be considered relevant. |
| Massive LVH | Wall thickness ≥30 mm in any segment within the chamber by echocardiography or CMR imaging; consideration for this morphologic marker is also given to borderline values of ≥28 mm in individual patients at the discretion of the treating cardiologist. For pediatric patients with HCM, an absolute or z-score threshold for wall thickness has not been established; however, a maximal wall that corresponds to a z-score ≥20 (and >10 in conjunction with other risk factors) appears reasonable. |
| Unexplained syncope | ≥1 Unexplained episodes involving acute transient loss of consciousness, judged by history unlikely to be of neurocardiogenic (vasovagal) etiology, nor attributable to LVOTO, and especially when occurring within 6 mo of evaluation (events beyond 5 y in the past do not appear to have relevance). |
| HCM with LV systolic dysfunction | Systolic dysfunction with EF <50% by echocardiography or CMR imaging. |
| LV apical aneurysm | Apical aneurysm defined as a discrete thin-walled dyskinetic or akinetic segment of the most distal portion of the LV chamber; independent of size. |
| Extensive LGE on CMR imaging | Diffuse and extensive LGE, representing fibrosis, either quantified or estimated by visual inspection, comprising ≥15% of LV mass (extent of LGE conferring risk has not been established in children). |
| NSVT on ambulatory monitor | It would seem most appropriate to place greater weight on NSVT as a risk marker when runs are frequent (≥3), longer (≥10 beats), and faster (≥200 bpm) occurring usually over 24 to 48 h of monitoring. For pediatric patients, a VT rate that exceeds the baseline sinus rate by >20% is considered significant. |

CMR indicates cardiovascular magnetic resonance; ICD, implantable cardioverter-defibrillator; LGE, late gadolinium enhancement; LV, left ventricular; LVH, left ventricular hypertrophy; LVOTO, left ventricular outflow tract obstruction; NSVT, nonsustained ventricular tachycardia; and SCD, sudden cardiac death.

4.3. Device Selection Considerations

Figure 3 presents ICD patient selection.

| Recommendations for Selection of ICD Device Type Referenced studies that support the recommendations are summarized in Online Data Supplement 13. | | |
|--|------|--|
| COR | LOE | Recommendations |
| 1 | B-NR | 1. In patients with HCM who are receiving an ICD, either a single chamber transvenous ICD or a subcutaneous ICD is recommended after a shared decision-making discussion that takes into consideration patient preferences, lifestyle, and expected potential need for pacing for bradycardia or ventricular tachycardia termination. ^{175–190} |
| 1 | B-NR | 2. In patients with HCM who are receiving an ICD, single-coil ICD leads are recommended in preference to dual coil leads. ¹⁸⁷ |
| 2a | B-NR | 3. In patients with HCM who are receiving an ICD, dual-chamber ICDs are reasonable for patients with a need for atrial or atrioventricular sequential pacing for bradycardia/conduction abnormalities, or as an attempt to relieve symptoms of obstructive HCM (most commonly in patients >65 years of age). ^{191–198} |
| 2a | C-LD | 4. In selected adult patients with nonobstructive HCM receiving an ICD who have NYHA class II to ambulatory class IV HF, left bundle branch block (LBBB), and LV ejection fraction (LVEF) <50%, cardiac resynchronization therapy for symptom reduction is reasonable. ^{199–203} |
| 2b | C-LD | 5. In patients with HCM in whom a decision has been made for ICD implantation and who have paroxysmal atrial tachycardias or AF, dual-chamber ICDs may be reasonable, but this decision must be balanced against higher complication rates of dual chamber devices. ^{191–198} |




Figure 3. ICD patient selection.

Colors correspond to the Class of Recommendation in Table 2. *ICD decisions in pediatric patients with HCM are based on ≥1 of these major risk factors: family history of HCM SCD, NSVT on ambulatory monitor, massive LVH, and unexplained syncope. †In patients >16 years of age, 5-year risk estimates can be considered to fully inform patients during shared decision-making discussions. ‡It would seem most appropriate to place greater weight on frequent, longer, and faster runs of NSVT. CMR indicates cardiovascular magnetic resonance; EF, ejection fraction; FH, family history; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter-defibrillator; LGE, late gadolinium enhancement; LVH, left ventricular hypertrophy; NSVT, nonsustained ventricular tachycardia; SCD, sudden cardiac death; VF, ventricular fibrillation; and VT, ventricular tachycardia.

5. MANAGEMENT OF HCM

5.1. Management of Symptomatic Patients With Obstructive HCM

5.1.1. Pharmacologic Management of Symptomatic Patients With Obstructive HCM

Tables in this section are located in the full guideline.¹

| Recommendations for Pharmacologic Management of Patients With Obstructive HCM Referenced studies that support the recommendations are summarized in Online Data Supplement 14. | | |
|---|----------------------------------|--|
| COR | LOE | Recommendations |
| 1 | B-NR | 1. In patients with obstructive HCM and symptoms* attributable to LVOTO, nonvasodilating beta blockers, titrated to effectiveness or maximally tolerated doses, are recommended. ^{204–206} |
| 1 | Verapamil B-NR Diltiazem C-LD | 2. In patients with obstructive HCM and symptoms* attributable to LVOTO, for whom beta blockers are ineffective or not tolerated, substitution with non-dihydropyridine calcium channel blockers (eg, verapamil, diltiazem) is recommended. ^{207–209} |
| 1 | B-NR | 3. For patients with obstructive HCM who have persistent severe symptoms* attributable to LVOTO despite beta blockers or non-dihydropyridine calcium channel blockers, either adding disopyramide in combination with 1 of the other drugs, or SRT performed at experienced centers,† is recommended. ^{17,50,210–213} |
| 1 | C-LD | 4. For patients with obstructive HCM and acute hypotension who do not respond to fluid administration, intravenous phenylephrine (or other vasoconstrictors without inotropic activity), alone or in combination with beta-blocking drugs, is recommended. ²¹⁴ |
| 2b | C-EO | 5. For patients with obstructive HCM and persistent dyspnea with clinical evidence of volume overload and high left-sided filling pressures despite other HCM guideline-directed management and therapy, cautious use of low-dose oral diuretics may be considered. |
| 2b | C-EO | 6. For patients with obstructive HCM, discontinuation of vasodilators (eg, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, dihydropyridine calcium channel blockers) or digoxin may be reasonable because these agents can worsen symptoms caused by dynamic outflow tract obstruction. |
| 3: Harm | C-LD | 7. For patients with obstructive HCM and severe dyspnea at rest, hypotension, very high resting gradients (eg, >100 mm Hg), as well as all children <6 weeks of age, verapamil is potentially harmful. ^{207,215} |

*Symptoms include effort-related dyspnea or chest pain; and occasionally other exertional symptoms (eg, syncope, near syncope) that are attributed to LVOTO and interfere with everyday activity or quality of life.

†Comprehensive or primary HCM centers with demonstrated excellence in clinical outcomes for these procedures (Table 3 and Table 4).

5.1.2. Invasive Treatment of Symptomatic Patients With Obstructive HCM

Tables in this section are located in the full guideline.¹ Figure 4 presents a management diagram of symptoms in patients with HCM.

| Recommendations for Invasive Treatment of Symptomatic Patients With Obstructive HCM Referenced studies that support the recommendations are summarized in Online Data Supplement 15. | | |
|---|------|--|
| COR | LOE | Recommendations |
| 1 | B-NR | 1. In patients with obstructive HCM who remain severely symptomatic despite guideline-directed management and therapy, SRT in eligible patients,* performed at experienced centers,† is recommended for relieving LVOTO. ^{17,50,213} (Table 3 and Table 4). |
| 1 | B-NR | 2. In symptomatic patients with obstructive HCM who have associated cardiac disease requiring surgical treatment (eg, associated anomalous papillary muscle, markedly elongated anterior mitral leaflet, intrinsic mitral valve disease, multivessel coronary artery disease, valvular aortic stenosis), surgical myectomy, performed at experienced centers,† is recommended. ^{92,216–218} (Table 3 and Table 4). |
| 1 | C-LD | 3. In adult patients with obstructive HCM who remain severely symptomatic, despite guideline-directed management and therapy and in whom surgery is contraindicated or the risk is considered unacceptable because of serious comorbidities or advanced age, alcohol septal ablation in eligible patients,* performed at experienced centers,† is recommended. ^{219–221} (Table 3 and Table 4). |
| 2b | B-NR | 4. In patients with obstructive HCM, earlier (NYHA class II) surgical myectomy performed at comprehensive HCM centers (Table 3 and Table 4), may be reasonable in the presence of additional clinical factors, including ^{17,222–233} : a. Severe and progressive pulmonary hypertension thought to be attributable to LVOTO or associated mitral regurgitation. b. Left atrial enlargement with ≥1 episodes of symptomatic AF. c. Poor functional capacity attributable to LVOTO as documented on treadmill exercise testing. d. Children and young adults with very high resting LVOT gradients (>100 mm Hg). |
| 2b | C-LD | 5. For severely symptomatic patients with obstructive HCM, SRT in eligible patients,* performed at experienced centers† (Table 3 and Table 4), may be considered as an alternative to escalation of medical therapy after shared decision-making including risks and benefits of all treatment options. ^{10,213,221,234,235} |
| 3: Harm | C-LD | 6. For patients with HCM who are asymptomatic and have normal exercise capacity, SRT is not recommended. ^{224,232} |
| 3: Harm | B-NR | 7. For symptomatic patients with obstructive HCM in whom SRT is an option, mitral valve replacement should not be performed for the sole purpose of relief of LVOTO. ^{236,237} |

*General eligibility criteria for septal reduction therapy: a) Clinical: Severe dyspnea or chest pain (usually NYHA functional class III or class IV), or occasionally other exertional symptoms (eg, syncope, near syncope), when attributable to LVOTO, that interferes with everyday activity or quality of life despite optimal medical therapy. b) Hemodynamic: Dynamic LVOT gradient at rest or with physiologic provocation with approximate peak gradient of ≥50 mm Hg, associated with septal hypertrophy and SAM of mitral valve. c) Anatomic: Targeted anterior septal thickness sufficient to perform the procedure safely and effectively in the judgment of the individual operator.

†Comprehensive or primary HCM centers with demonstrated excellence in clinical outcomes for these procedures (Table 3 and Table 4).




Figure 4. Management of symptoms in patients with HCM.

Colors correspond to the Class of Recommendation in Table 2. GL indicates guideline; HCM, hypertrophic cardiomyopathy; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; and SRT, septal reduction therapy.

Downloaded from <http://ahajournals.org> by on April 20, 2024

5.2. Management of Patients With Nonobstructive HCM With Preserved EF

| Recommendations for Management of Patients With Nonobstructive HCM With Preserved EF Referenced studies that support the recommendations are summarized in Online Data Supplement T5. | | |
|--|------|--|
| COR | LOE | Recommendations |
| 1 | C-LD | 1. In patients with nonobstructive HCM with preserved EF and symptoms of exertional angina or dyspnea, beta blockers or non-dihydropyridine calcium channel blockers are recommended. ^{209,238-246} |
| 2a | C-EO | 2. In patients with nonobstructive HCM with preserved EF, it is reasonable to add oral diuretics when exertional dyspnea persists despite the use of beta blockers or non-dihydropyridine calcium channel blockers. |
| 2b | C-LD | 3. In patients with nonobstructive HCM with preserved EF, the usefulness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the treatment of symptoms (angina and dyspnea) is not well established. ²⁴⁷ |
| 2b | C-LD | 4. In highly selected patients with apical HCM with severe dyspnea or angina (NYHA class III or class IV) despite maximal medical therapy, and with preserved EF and small LV cavity size (LV end-diastolic volume <50 mL/m ² and LV stroke volume <30 mL/m ²), apical myectomy by experienced surgeons at comprehensive centers may be considered to reduce symptoms. ²⁴⁸ |
| 2b | C-EO | 5. In asymptomatic patients with non-obstructive HCM, the benefit of beta blockers or calcium channel blockers is not well established. |

5.3. Management of Patients With HCM and Atrial Fibrillation

| Recommendations for Management of Atrial Fibrillation Referenced studies that support the recommendations are summarized in Online Data Supplement 16. | | |
|---|------|--|
| COR | LOE | Recommendations |
| 1 | B-NR | 1. In patients with HCM and clinical AF, anticoagulation is recommended with direct-acting oral anticoagulants as first-line option and vitamin K antagonists as second-line option, independent of CHA ₂ DS ₂ -VASc score. ²⁴⁹⁻²⁵³ |
| 1 | C-LD | 2. In patients with HCM and subclinical AF detected by internal or external cardiac device or monitor of >24 hours' duration for a given episode, anticoagulation is recommended with direct-acting oral anticoagulants as first-line option and vitamin K antagonists as second-line option, independent of CHA ₂ DS ₂ -VASc score. ^{102,103,249,254} |
| 1 | C-LD | 3. In patients with AF in whom rate control strategy is planned, either beta blockers, verapamil, or diltiazem are recommended, with the choice of agents according to patient preferences and comorbid conditions. ^{104,255} |
| 2a | C-LD | 4. In patients with HCM and subclinical AF detected by internal or external device or monitor, of >5 minutes' but <24 hours' duration for a given episode, anticoagulation with direct-acting oral anticoagulants as first-line option and vitamin K antagonists as second-line option can be beneficial, taking into consideration duration of AF episodes, total AF burden, underlying risk factors, and bleeding risk. ^{102,103,249,254,256} |

| Recommendations for Management of Atrial Fibrillation (Continued) | | |
|---|------|--|
| COR | LOE | Recommendations |
| 2a | B-NR | 5. In patients with HCM and poorly tolerated AF, a rhythm control strategy with cardioversion or antiarrhythmic drugs can be beneficial with the choice of an agent according to AF symptom severity, patient preferences, and comorbid conditions. ^{104,210,257-268} |
| 2a | B-NR | 6. In patients with HCM and symptomatic AF, as part of a AF rhythm control strategy, catheter ablation for AF can be effective when drug therapy is ineffective, contraindicated, or not the patient's preference. ^{257,269,270} |
| 2a | B-NR | 7. In patients with HCM and AF who require surgical myectomy, concomitant surgical AF ablation procedure can be beneficial for AF rhythm control. ^{104,258,271-273} |

5.4. Management of Patients With HCM and Ventricular Arrhythmias

| Recommendations for the Management of Patients With HCM and Ventricular Arrhythmias Referenced studies that support the recommendations are summarized in Online Data Supplement 17. | | |
|---|---|---|
| COR | LOE | Recommendations |
| 1 | B-NR | 1. In patients with HCM and recurrent poorly tolerated life-threatening ventricular tachyarrhythmias refractory to maximal antiarrhythmic drug therapy and ablation, heart transplantation assessment is indicated in accordance with current listing criteria. ^{21,274} |
| 1 | Amiodarone, B-NR Dofetilide, C-LD Mexiletine, C-LD Sotalol, C-LD | 2. In adults with HCM and symptomatic ventricular arrhythmias or recurrent ICD shocks despite beta-blocker use, antiarrhythmic drug therapy listed is recommended, with the choice of agent guided by age, underlying comorbidities, severity of disease, patient preferences, and balance between efficacy and safety. ²⁷⁵⁻²⁷⁸ |
| 1 | C-LD | 3. In children with HCM and recurrent ventricular arrhythmias despite beta-blocker use, antiarrhythmic drug therapy (amiodarone, ^{275,276} mexiletine, ²⁷⁸ sotalol ^{275,276}) is recommended, with the choice of agent guided by age, underlying comorbidities, severity of disease, patient preferences, and balance of efficacy and safety. |
| 1 | C-LD | 4. In patients with HCM and pacing-capable ICDs, programming antitachycardia pacing is recommended to minimize risk of shocks. ^{279,280} |
| 2a | C-LD | 5. In patients with HCM and recurrent symptomatic sustained monomorphic ventricular tachycardia, or recurrent ICD shocks despite optimal device programming, and in whom antiarrhythmic drug therapy is either ineffective, not tolerated, or not preferred, catheter ablation can be useful for reducing arrhythmia burden. ^{20,281,282} |

5.5. Management of Patients With HCM and Advanced HF

Figure 5 presents a heart failure algorithm.




Figure 5. Heart failure algorithm.

Colors correspond to the Class of Recommendation in Table 2. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitors; CRT, cardiac resynchronization therapy; EF, ejection fraction; GDMT, guideline-directed management and therapy; HCM, hypertrophic cardiomyopathy; LBBB, left bundle branch block; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; and NYHA, New York Heart Association.

Downloaded from <http://ahajournals.org> by on April 20, 2024

| Recommendations for Patients With HCM and Advanced HF Referenced studies that support the recommendations are summarized in Online Data Supplement 18. | | |
|---|------|--|
| COR | LOE | Recommendations |
| 1 | C-LD | 1. In patients with HCM who develop systolic dysfunction with an LVEF <50%, guideline-directed therapy for HF with reduced EF is recommended. ^{38,283,284} |
| 1 | C-LD | 2. In patients with HCM and systolic dysfunction, diagnostic testing to assess for concomitant causes of systolic dysfunction (such as coronary artery disease) is recommended. ^{22,36,285} |
| 1 | B-NR | 3. In patients with nonobstructive HCM and advanced HF (NYHA functional class III to class IV despite guideline-directed therapy) cardiopulmonary exercise test should be performed to quantify the degree of functional limitation and aid in selection of patients for heart transplantation or mechanical circulatory support. ^{113,114} |
| 1 | B-NR | 4. In patients with nonobstructive HCM and advanced HF (NYHA class III to class IV despite guideline-directed therapy) or with life-threatening ventricular arrhythmias refractory to maximal guideline-directed therapy, assessment for heart transplantation in accordance with current listing criteria is recommended. ^{21,274,286,287} |
| 2a | C-EO | 5. For patients with HCM who develop systolic dysfunction (LVEF <50%), it is reasonable to discontinue previously indicated negative inotropic agents (specifically, verapamil, diltiazem, or disopyramide). |
| 2a | B-NR | 6. In patients with nonobstructive HCM and advanced HF (NYHA functional class III to class IV despite GDMT) who are candidates for heart transplantation, continuous-flow LV assist device therapy is reasonable as a bridge to heart transplantation. ^{288–291} |
| 2a | C-LD | 7. In patients with HCM and LVEF <50%, ICD placement can be beneficial. ²⁸⁴ |
| 2a | C-LD | 8. In patients with HCM and LVEF <50%, NYHA functional class II to class IV symptoms despite guideline-directed therapy, and LBBB, CRT can be beneficial to improve symptoms. ^{199–203} |

6. LIFESTYLE CONSIDERATIONS FOR PATIENTS WITH HCM

6.1. Sports and Activity

| Recommendations for Sports and Activity Referenced studies that support the recommendations are summarized in Online Data Supplement 19. | | |
|---|------|---|
| COR | LOE | Recommendations |
| 1 | B-NR | 1. For most patients with HCM, mild- to moderate-intensity recreational* exercise is beneficial to improve cardiorespiratory fitness, physical functioning, and quality of life, and for their overall health in keeping with physical activity guidelines for the general population. ^{292–294} |

| Recommendations for Sports and Activity (Continued) | | |
|---|------|--|
| COR | LOE | Recommendations |
| 1 | C-EO | 2. For athletes with HCM, a comprehensive evaluation and shared discussion of potential risks of sports participation by an expert provider is recommended. ²⁹⁵ |
| 2a | C-EO | 3. For most patients with HCM, participation in low-intensity competitive sports is reasonable. ^{2,297} |
| 2a | C-LD | 4. In individuals who are genotype-positive, phenotype-negative for HCM, participation in competitive athletics of any intensity is reasonable. ^{2,174,297–301} |
| 2b | C-LD | 5. For patients with HCM, participation in high-intensity recreational activities or moderate- to high-intensity competitive sports activities may be considered after a comprehensive evaluation and shared discussion, repeated annually with an expert provider who conveys that the risk of sudden death and ICD shocks may be increased, and with the understanding that eligibility decisions for competitive sports participation often involve third parties (eg, team physicians, consultants, and other institutional leadership) acting on behalf of the schools or teams. ^{174,295,298–301} |
| 3: Harm | B-NR | 6. In patients with HCM, ICD placement for the sole purpose of participation in competitive athletics should not be performed. ^{2,174,302} |

*Recreational exercise is done for the purpose of leisure with no requirement for systematic training and without the purpose to excel or compete against others.

6.2. Occupation

| Recommendations for Occupation in Patients With HCM | | |
|---|------|--|
| COR | LOE | Recommendations |
| 2a | C-EO | 1. For patients with HCM, it is reasonable to follow Federal Motor Carrier Safety Administration cardiovascular disease guidelines that permit driving commercial motor vehicles, if they do not have an ICD or any major risk factors for SCD and are following a guideline-directed management plan. ³⁰³ |
| 2a | C-EO | 2. For pilot aircrew with a diagnosis of HCM, it is reasonable to follow Federal Aviation Administration guidelines that permit consideration of multicrew flying duties, provided they are asymptomatic, are deemed low risk for SCD, and can complete a maximal treadmill stress test at 85% peak heart rate. ³⁰⁴ |
| 2b | C-EO | 3. Patients with HCM may consider occupations that require manual labor, heavy lifting, or a high level of physical performance after a comprehensive clinical evaluation, risk stratification for SCD, and implementation of guideline-directed management. Before a shared decision between a clinician and patient is reached, the clinician should convey that risks associated with the physical requirements of these occupations are uncertain. |

6.3. Pregnancy

| Recommendations for Pregnancy in Patients With HCM Referenced studies that support the recommendations are summarized in Online Data Supplement 28. | | |
|--|------|--|
| COR | LOE | Recommendations |
| 1 | B-NR | 1. For pregnant women with HCM and AF or other indications for anticoagulation, low-molecular-weight heparin or vitamin K antagonists (at maximum therapeutic dose of <5 mg daily) are recommended for stroke prevention. ^{249,250,305} |
| 1 | C-LD | 2. In pregnant women with HCM, selected beta blockers should be administered for symptoms related to outflow tract obstruction or arrhythmias, with monitoring of fetal growth. ^{306,307} |
| 1 | C-LD | 3. In most pregnant women with HCM, vaginal delivery is recommended as the first-choice delivery option. ^{306,308} |
| 1 | B-NR | 4. In affected families with HCM, preconceptional and prenatal reproductive and genetic counseling should be offered. ^{302,306,307,308} |
| 1 | C-EO | 5. For pregnant women with HCM, care should be coordinated between their cardiologist and an obstetrician. For patients with HCM who are deemed high risk, consultation is advised with an expert in maternal-fetal medicine. |
| 2a | C-LD | 6. For women with clinically stable HCM who wish to become pregnant, it is reasonable to advise that pregnancy is generally safe as part of a shared discussion regarding potential maternal and fetal risks, and initiation of guideline-directed therapy. ³⁰⁹⁻³¹² |
| 2a | C-LD | 7. In pregnant women with HCM, cardioversion for new or recurrent AF, particularly if symptomatic, is reasonable. ^{302,313} |
| 2a | C-LD | 8. In pregnant women with HCM, general or epidural anesthesia is reasonable, with precautions to avoid hypotension. ³¹⁰ |
| 2a | C-EO | 9. In pregnant women with HCM, it is reasonable to perform serial echocardiography, particularly during the second or third trimester when hemodynamic load is highest, or if clinical symptoms develop. ³⁰⁹ |
| 2b | C-EO | 10. In pregnant women with HCM, fetal echocardiography may be considered for diagnosis of fetal HCM in the context of prenatal counseling. |

6.4. Comorbidities

Table 9 addresses lifestyle considerations for patients with HCM.

| Recommendations for Patients With Comorbidities Referenced studies that support the recommendations are summarized in Online Data Supplement 27. | | |
|---|------|---|
| COR | LOE | Recommendations |
| 1 | C-EO | 1. In patients with HCM, adherence to the guidelines on the prevention of atherosclerotic cardiovascular disease is recommended to reduce risk of cardiovascular events. ²⁹⁴ |
| 1 | B-NR | 2. In patients with HCM who are overweight or obese, counseling and comprehensive lifestyle interventions are recommended for achieving and maintaining weight loss ²⁹⁴ and possibly lowering the risk of developing LVOTO, HF, and AF. ³¹⁴⁻³¹⁶ |

| Recommendations for Patients With Comorbidities (Continued) | | |
|---|------|---|
| COR | LOE | Recommendations |
| 1 | C-LD | 3. In patients with HCM and hypertension, lifestyle modifications and medical therapy for hypertension are recommended ²⁹⁴ with preference for beta blockers and non-dihydropyridine calcium channel blockers in patients with obstructive HCM. ^{310,316-319} |
| 1 | C-LD | 4. In patients with HCM, assessment for symptoms of sleep disordered breathing is recommended and, if present, referral to a sleep medicine specialist for evaluation and treatment. ³²⁰⁻³²³ |

Table 9. Lifestyle Considerations for Patients With HCM

| Lifestyle Considerations* | |
|---------------------------|---|
| Sports/activity | For most patients with HCM, mild- to moderate-intensity recreational exercise is beneficial to improve cardiorespiratory fitness, physical functioning, and quality of life, and for their overall health in keeping with physical activity guidelines for the general population |
| Pregnancy | For women with clinically stable HCM who wish to become pregnant, it is reasonable to advise that pregnancy is generally safe as part of a shared discussion regarding potential maternal and fetal risks, and initiation of guideline-directed therapy. |
| Comorbidities | The clinician should monitor and counsel patients on prevention and treatment of comorbid conditions that can worsen severity of HCM (atherosclerotic cardiovascular disease, obesity, hypertension, sleep-disordered breathing) |

*Shared decision-making is an important component of counseling and lifestyle modifications.
HCM indicates hypertrophic cardiomyopathy.

ACC/AHA JOINT COMMITTEE MEMBERS

Patrick T. O’Gara, MD, MACC, FAHA, Chair; Joshua A. Beckman, MD, MS, FAHA, Chair-Elect; Glenn N. Levine, MD, FACC, FAHA, Immediate Past Chair*; Sana M. Al-Khatib, MD, MHS, FACC, FAHA*; Anastasia Armbruster, PharmD, AACC; Kim K. Birtcher, PharmD, MS, AACC; Joaquin Cigarroa, MD, FACC*; Dave L. Dixon, PharmD, FACC; Lisa de las Fuentes, MD, MS, FAHA, FASE; Anita Deswal, MD, MPH, FACC, FAHA; Lee A. Fleisher, MD, FACC, FAHA*; Federico Gentile, MD, FACC*; Zachary D. Goldberger, MD, MSc, FACC, FAHA; Bulent Gorenek, MD, FACC; Norrisa Haynes, MD, MPH; Adrian F. Hernandez, MD, MHS; Mark A. Hlatky, MD, FACC, FAHA*; José A. Joglar, MD, FACC, FAHA; W. Schuyler Jones, MD, FACC; Joseph E. Marine, MD, FACC*; Daniel Mark, MD, MPH, FACC, FAHA; Latha Palaniappan, MD, MS, FAHA, FACC; Mariann R. Piano, RN, PhD, FAHA; Jacqueline Tamis-Holland, MD, FACC; Duminda N. Wijeyesundera, MD, PhD*; Y. Joseph Woo, MD, FACC, FAHA

*Former Joint Committee on Clinical Practice Guidelines member; current member during the writing effort.

ARTICLE INFORMATION

This document was approved by the American College of Cardiology Clinical Policy Approval Committee in August 2020, the American Heart Association Science Advisory and Coordinating Committee in August 2020, and the American Heart Association Executive Committee in October 2020.

This article has been copublished in the *Journal of the American College of Cardiology*.

Copies: This document is available on the websites of the American College of Cardiology (www.acc.org) and the American Heart Association (professional.heart.org). A copy of the document is also available at <https://professional.heart.org/statements> by selecting the "Guidelines & Statements" button. To purchase additional reprints, call 215-356-2721 or email Meredith.Edelman@wolterskluwer.com.

The expert peer review of AHA-commissioned documents (eg, scientific statements, clinical practice guidelines, systematic reviews) is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit <https://professional.heart.org/statements>. Select the "Guidelines & Statements" drop-down menu near the top of the webpage, then click "Publication Development."

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at <https://www.heart.org/permissions>. A link to the "Copyright Permissions Request Form" appears in the second paragraph (<https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form>).

REFERENCES

- Ommen S, Mital S, Burke M, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2020;142:e558–e631.
- Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation*. 2011;124:e783–831.
- ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. American College of Cardiology and American Heart Association, 2010. Available at: https://professional.heart.org/-/media/pdf-files/guidelines-and-statements/methodology_manual_and_policies_ucm_319826.pdf. Accessed August 19, 2020.
- Agency for Healthcare Research and Quality. Strategy 6I: Shared Decision-making. In: The CAHPS Ambulatory Care Improvement Guide: Practical Strategies for Improving Patient Experience. Available at: <https://www.ahrq.gov/cahps/quality-improvement/improvement-guide/6-strategies-for-improving/communication/strategy6i-shared-decisionmaking.html>. Accessed April 29, 2020.
- Agency for Healthcare Research and Quality. AHRQ Health Literacy Universal Precautions Toolkit, 2nd ed. Content last reviewed May 2020. Rockville, MD. Available at: <https://www.ahrq.gov/health-literacy/quality-resources/tools/literacy-toolkit/index.html>. Accessed June 20, 2020.
- Greenfield S, Kaplan SH, Ware JE Jr, et al. Patients' participation in medical care: effects on blood sugar control and quality of life in diabetes. *J Gen Intern Med*. 1988;3:448–57.
- Greenfield S, Kaplan S, Ware JE Jr. Expanding patient involvement in care. Effects on patient outcomes. *Ann Intern Med*. 1985;102:520–8.
- Kaplan SH, Greenfield S, Ware JE Jr. Assessing the effects of physician-patient interactions on the outcomes of chronic disease. *Med Care*. 1989;27:S110–27.
- Guadagnoli E, Ward P. Patient participation in decision-making. *Soc Sci Med*. 1998;47:329–39.
- Kim LK, Swaminathan RV, Looser P, et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003–2011. *JAMA Cardiol*. 2016;1:324–32.
- Panaich SS, Badheka AO, Chothani A, et al. Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide Inpatient Sample [1998–2010]). *Am J Cardiol*. 2014;114:1390–95.
- Sorajja P, Ommen SR, Holmes DR Jr, et al. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. *Circulation*. 2012;126:2374–80.
- Maron BJ, Nishimura RA, Maron MS. Shared decision-making in HCM. *Nat Rev Cardiol*. 2017;14:125–6.
- Chambers JB, Prendergast B, Lung B, et al. Standards defining a 'Heart Valve Centre': ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint. *Eur Heart J*. 2017;38:2177–83.
- Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2015;65:1249–54.
- Maron BJ, Ommen SR, Semsarian C, et al. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. *J Am Coll Cardiol*. 2014;64:83–99.
- Ommen SR, Maron BJ, Olivetto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2005;46:470–6.
- Desai MY, Bhonsale A, Smedira NG, et al. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. *Circulation*. 2013;128:209–16.
- Lim KK, Maron BJ, Knight BP. Successful catheter ablation of hemodynamically unstable monomorphic ventricular tachycardia in a patient with hypertrophic cardiomyopathy and apical aneurysm. *J Cardiovasc Electrophysiol*. 2009;20:445–7.
- Dukkipati SR, d'Avila A, Soejima K, et al. Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy. *Circ Arrhythm Electrophysiol*. 2011;4:185–94.
- Rowin EJ, Maron BJ, Abt P, et al. Impact of advanced therapies for improving survival to heart transplant in patients with hypertrophic cardiomyopathy. *Am J Cardiol*. 2018;121:986–96.
- Pasqualucci D, Fornaro A, Castelli G, et al. Clinical spectrum, therapeutic options, and outcome of advanced heart failure in hypertrophic cardiomyopathy. *Circ Heart Fail*. 2015;8:1014–21.
- Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. *J Am Coll Cardiol*. 2012;60:705–15.
- Ingles J, Yeates L, Semsarian C. The emerging role of the cardiac genetic counselor. *Heart Rhythm*. 2011;8:1958–62.
- Ahmad F, McNally EM, Ackerman MJ, et al. Establishment of specialized clinical cardiovascular genetics programs: recognizing the need and meeting standards: a scientific statement from the American Heart Association. *Circ Genom Precis Med* 2019;12:e0000054.
- van Velzen HG, Schinkel AFL, Baart SJ, et al. Outcomes of contemporary family screening in hypertrophic cardiomyopathy. *Circ Genom Precis Med* 2018;11:e001896.
- Ranthe MF, Carstensen L, Oyen N, et al. Risk of cardiomyopathy in younger persons with a family history of death from cardiomyopathy: a nationwide family study in a cohort of 3.9 million persons. *Circulation*. 2015;132:1013–9.
- Lafreniere-Roula M, Bolkier Y, Zahavich L, et al. Family screening for hypertrophic cardiomyopathy: is it time to change practice guidelines?. *Eur Heart J*. 2019;40:3672–81.
- Adabag AS, Kuskowski MA, Maron BJ. Determinants for clinical diagnosis of hypertrophic cardiomyopathy. *Am J Cardiol*. 2006;98:1507–11.
- Afonso LC, Bernal J, Bax JJ, et al. Echocardiography in hypertrophic cardiomyopathy: the role of conventional and emerging technologies. *J Am Coll Cardiol Img*. 2008;1:787–800.
- Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. *J Am Coll Cardiol*. 1995;26:1699–708.
- Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. *Prog Cardiovasc Dis*. 1985;28:1–83.
- Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. *J Am Coll Cardiol*. 1983;2:437–44.
- Nagueh SF, Bierig SM, Budoff MJ, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy. *J Am Soc Echocardiogr*. 2011;24:473–98.

35. Douglas PS, Garcia MJ, Haines DE, et al. ACCF/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography. a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. *J Am Coll Cardiol*. 2011;57:1126–66.
36. Melacini P, Basso C, Angelini A, et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. *Eur Heart J*. 2010;31:2111–23.
37. Thaman R, Gimeno JR, Murphy RT, et al. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. *Heart*. 2005;91:920–5.
38. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. *Circulation*. 2006;114:216–25.
39. Olivetto I, Cecchi F, Poggesi C, et al. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. *Circ Heart Fail*. 2012;5:535–46.
40. Todiere G, Aquaro GD, Piaggi P, et al. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2012;60:922–9.
41. Norrish G, Ding T, Field E, et al. A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy. *Europace*. 2019;21:1559–65.
42. Balaji S, DiLorenzo MP, Fish FA, et al. Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: an international multicenter study. *Heart Rhythm*. 2019;16:1462–7.
43. Maron MS, Olivetto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. *N Engl J Med*. 2003;348:295–303.
44. Woo A, Williams WG, Choi R, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. *Circulation*. 2005;111:2033–41.
45. Geske JB, Sorajja P, Nishimura RA, et al. Evaluation of left ventricular filling pressures by doppler echocardiography in patients with hypertrophic cardiomyopathy. *Circulation*. 2007;116:2702–8.
46. Rakowski H, Carasso S. Quantifying diastolic function in hypertrophic cardiomyopathy: the ongoing search for the holy grail. *Circulation*. 2007;116:2662–65.
47. Kumar S, Van Ness G, Bender A, et al. Standardized goal-directed Valsalva maneuver for assessment of inducible left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. *J Am Soc Echocardiogr*. 2018;31:791–8.
48. Marwick TH, Nakatani S, Haluska B, et al. Provocation of latent left ventricular outflow tract gradients with amyl nitrite and exercise in hypertrophic cardiomyopathy. *Am J Cardiol*. 1995;75:805–9.
49. Joshi S, Patel UK, Yao SS, et al. Standing and exercise Doppler echocardiography in obstructive hypertrophic cardiomyopathy: the range of gradients with upright activity. *J Am Soc Echocardiogr*. 2011;24:75–82.
50. Maron MS, Olivetto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. *Circulation*. 2006;114:2232–9.
51. Ayoub C, Geske JB, Larsen CM, et al. Comparison of Valsalva maneuver, amyl nitrite, and exercise echocardiography to demonstrate latent left ventricular outflow obstruction in hypertrophic cardiomyopathy. *Am J Cardiol*. 2017;120:2265–71.
52. Jensen MK, Havndrup O, Pecini R, et al. Comparison of Valsalva manoeuvre and exercise in echocardiographic evaluation of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. *Eur J Echocardiogr*. 2010;11:763–9.
53. Reant P, Dufour M, Peyrou J, et al. Upright treadmill vs. semi-supine bicycle exercise echocardiography to provoke obstruction in symptomatic hypertrophic cardiomyopathy: A pilot study. *Eur Heart J Cardiovasc Imaging*. 2018;19:31–8.
54. Shah JS, Esteban MT, Thaman R, et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. *Heart*. 2008;94:1288–94.
55. Grigg LE, Wigle ED, Williams WG, et al. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. *J Am Coll Cardiol*. 1992;20:42–52.
56. Marwick TH, Stewart WJ, Lever HM, et al. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 1992;20:1066–72.
57. Nampiaparampil RG, Swistel DG, Schlam M, et al. Intraoperative two- and three-dimensional transesophageal echocardiography in combined myectomy-mitral operations for hypertrophic cardiomyopathy. *J Am Soc Echocardiogr*. 2018;31:289–96.
58. Ommen SR, Park SH, Click RL, et al. Impact of intraoperative transesophageal echocardiography in the surgical management of hypertrophic cardiomyopathy. *Am J Cardiol*. 2002;90:1022–4.
59. Faber L, Seggewiss H, Ziemssen P, et al. Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area. *Catheter Cardiovasc Interv*. 1999;47:462–6.
60. Faber L, Ziemssen P, Seggewiss H. Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. *J Am Soc Echocardiogr*. 2000;13:1074–9.
61. Nagueh SF, Zoghbi WA. Role of imaging in the evaluation of patients at risk for sudden cardiac death: genotype-phenotype intersection. *J Am Coll Cardiol Img*. 2015;8:828–45.
62. Faber L, Seggewiss H, Welge D, et al. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. *Eur J Echocardiogr*. 2004;5:347–55.
63. Kuhn H, Gietzen FH, Schäfers M, et al. Changes in the left ventricular outflow tract after transcatheter ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion. *Eur Heart J*. 1999;20:1808–17.
64. Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. *Circulation*. 2008;118:131–9.
65. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. *Circulation*. 1998;98:2415–21.
66. Qin JX, Shiota T, Lever HM, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. *J Am Coll Cardiol*. 2001;38:1994–2000.
67. Jensen Morten K, Havndrup O, Christiansen M, et al. Penetrance of hypertrophic cardiomyopathy in children and adolescents. *Circulation*. 2013;127:48–54.
68. Deleted in proof.
69. Maurizi N, Michels M, Rowin EJ, et al. Clinical course and significance of hypertrophic cardiomyopathy without left ventricular hypertrophy. *Circulation*. 2019;139:830–3.
70. Norrish G, Jager J, Field E, et al. Yield of clinical screening for hypertrophic cardiomyopathy in child first-degree relatives. *Circulation*. 2019;140:184–92.
71. Vermeer AMC, Clur S-AB, Blom NA, et al. Penetrance of hypertrophic cardiomyopathy in children who are mutation positive. *J Pediatr*. 2017;188:91–5.
72. Thanigaraj S, Pérez JE. Apical hypertrophic cardiomyopathy: echocardiographic diagnosis with the use of intravenous contrast image enhancement. *J Am Soc Echocardiogr*. 2000;13:146–9.
73. Porter TR, Mulvagh SL, Abdelmoneim SS, et al. Clinical applications of ultrasonic enhancing agents in echocardiography: 2018 American Society of Echocardiography guidelines update. *J Am Soc Echocardiogr*. 2018;31:241–74.
74. Maron MS, Maron BJ, Harrigan C, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. *J Am Coll Cardiol*. 2009;54:220–8.
75. Rickers C, Wilke NM, Jerosch-Herold M, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. *Circulation*. 2005;112:855–61.
76. Moon JC, Fisher NG, McKenna WJ, et al. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. *Heart*. 2004;90:645–9.
77. Hindieh W, Weissler-Snir A, Hammer H, et al. Discrepant measurements of maximal left ventricular wall thickness between cardiac magnetic

resonance imaging and echocardiography in patients with hypertrophic cardiomyopathy. *Circ Cardiovasc Imaging*. 2017;10:e006309.

78. Corona-Villalobos CP, Sorensen LL, Pozios I, et al. Left ventricular wall thickness in patients with hypertrophic cardiomyopathy: a comparison between cardiac magnetic resonance imaging and echocardiography. *Int J Cardiovasc Imaging*. 2016;32:945–54.
79. Bois JP, Geske JB, Foley TA, et al. Comparison of maximal wall thickness in hypertrophic cardiomyopathy differs between magnetic resonance imaging and transthoracic echocardiography. *Am J Cardiol*. 2017;119:643–50.
80. Maron MS, Rowin EJ, Maron BJ. How to image hypertrophic cardiomyopathy. *Circ Cardiovasc Imaging* 10;2017.
81. Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. *J Am Coll Cardiol*. 2017;69:761–73.
82. Kebed KY, Al Adham RI, Bishu K, et al. Evaluation of apical pouches in hypertrophic cardiomyopathy using cardiac MRI. *Int J Cardiovasc Imaging*. 2014;30:591–7.
83. Maron MS, Lesser JR, Maron BJ. Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance. *Am J Cardiol*. 2010;105:1842–3.
84. Weng Z, Yao J, Chan RH, et al. Prognostic value of LGE-CMR in HCM: a meta-analysis. *J Am Coll Cardiol Img*. 2016;9:1392–402.
85. Chan RH, Maron BJ, Olivetto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. *Circulation*. 2014;130:484–95.
86. Mentias A, Raeisi-Giglou P, Smedira NG, et al. Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function. *J Am Coll Cardiol*. 2018;72:857–70.
87. Ismail TF, Jabbour A, Gulati A, et al. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. *Heart*. 2014;100:1851–8.
88. Patel P, Dhillon A, Popovic ZB, et al. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy: implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography. *Circ Cardiovasc Imaging*. 2015;8:e003132.
89. Rowin EJ, Maron BJ, Chokshi A, et al. Clinical spectrum and management implications of left ventricular outflow obstruction with mild ventricular septal thickness in hypertrophic cardiomyopathy. *Am J Cardiol*. 2018;122:1409–20.
90. Sherrid MV, Balaran S, Kim B, et al. The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context. *J Am Coll Cardiol*. 2016;67:1846–58.
91. Kwon DH, Setser RM, Thamilarasan M, et al. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. *Heart*. 2008;94:1295–301.
92. Rowin EJ, Maron BJ, Lesser JR, et al. Papillary muscle insertion directly into the anterior mitral leaflet in hypertrophic cardiomyopathy, its identification and cause of outflow obstruction by cardiac magnetic resonance imaging, and its surgical management. *Am J Cardiol*. 2013;111:1677–9.
93. Langer C, Lutz M, Eden M, et al. Hypertrophic cardiomyopathy in cardiac CT: a validation study on the detection of intramyocardial fibrosis in consecutive patients. *Int J Cardiovasc Imaging*. 2014;30:659–67.
94. Zhao L, Ma X, Feuchtner GM, et al. Quantification of myocardial delayed enhancement and wall thickness in hypertrophic cardiomyopathy: multi-detector computed tomography versus magnetic resonance imaging. *Eur J Radiol*. 2014;83:1778–85.
95. Maron BJ. The electrocardiogram as a diagnostic tool for hypertrophic cardiomyopathy: revisited. *Ann Noninvasive Electrocardiol*. 2001;6:277–9.
96. Panza JA, Maron BJ. Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy during childhood. *Am J Cardiol*. 1989;63:1258–65.
97. Zorzi A, Calore C, Vio R, et al. Accuracy of the ECG for differential diagnosis between hypertrophic cardiomyopathy and athlete's heart: comparison between the European Society of Cardiology (2010) and International (2017) criteria. *Br J Sports Med*. 2018;52:667–73.
98. Maron BJ, Savage DD, Wolfson JK, et al. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. *Am J Cardiol*. 1981;48:252–7.
99. Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. *J Am Coll Cardiol*. 2003;42:873–9.
100. Adabag AS, Casey SA, Kuskowski MA, et al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2005;45:697–704.
101. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation*. 2017;136:e60–122.
102. Wilke I, Witzel K, Münch J, et al. High incidence of de novo and sub-clinical atrial fibrillation in patients with hypertrophic cardiomyopathy and cardiac rhythm management device. *J Cardiovasc Electrophysiol*. 2016;27:779–84.
103. van Velzen HG, Theuns DA, Yap SC, et al. Incidence of device-detected atrial fibrillation and long-term outcomes in patients with hypertrophic cardiomyopathy. *Am J Cardiol*. 2017;119:100–5.
104. Rowin EJ, Hausvater A, Link MS, et al. Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. *Circulation*. 2017;136:2420–36.
105. Rowin EJ, Orfanos A, Estes NAM, et al. Occurrence and natural history of clinically silent episodes of atrial fibrillation in hypertrophic cardiomyopathy. *Am J Cardiol*. 2017;119:1862–5.
106. Siontis KC, Geske JB, Ong K, et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. *J Am Heart Assoc*. 2014;3:e001002.
107. Geske JB, Sorajja P, Ommen SR, et al. Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol Intv*. 2011;4:704–9.
108. Prasad M, Geske JB, Sorajja P, et al. Hemodynamic changes in systolic and diastolic function during isoproterenol challenge predicts symptomatic response to myectomy in hypertrophic cardiomyopathy with labile obstruction. *Catheter Cardiovasc Interv*. 2016;88:962–70.
109. Elesber A, Nishimura RA, Rihal CS, et al. Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy. *Am J Cardiol*. 2008;101:516–20.
110. Sorajja P, Ommen SR, Nishimura RA, et al. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. *Circulation*. 2003;108:2342–8.
111. Thalji NM, Suri RM, Daly RC, et al. Assessment of coronary artery disease risk in 5463 patients undergoing cardiac surgery: When is pre-operative coronary angiography necessary?. *J Thorac Cardiovasc Surg*. 2013;146:1055–10564.e1.
112. Ciampi Q, Betocchi S, Lombardi R, et al. Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2002;40:278–84.
113. Coats CJ, Rantell K, Bartnik A, et al. Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy. *Circ Heart Fail*. 2015;8:1022–31.
114. Magri D, Re F, Limongelli G, et al. Heart failure progression in hypertrophic cardiomyopathy-possible insights from cardiopulmonary exercise testing. *Circ J*. 2016;80:2204–11.
115. Argulian E, Messerli FH, Aziz EF, et al. Antihypertensive therapy in hypertrophic cardiomyopathy. *Am J Cardiol*. 2013;111:1040–5.
116. Deleted in proof.
117. Charron P, Arad M, Arbustini E, et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J*. 2010;31:2715–26.
118. Ingles J, Sarina T, Yeates L, et al. Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. *Genet Med*. 2013;15:972–7.
119. Alfares AA, Kelly MA, McDermott G, et al. Results of clinical genetic testing of 2 912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. *Genet Med*. 2015;17:880–8.
120. Bagnall RD, Ingles J, Dinger ME, et al. Whole genome sequencing improves outcomes of genetic testing in patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2018;72:419–29.
121. Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRE). *Circulation*. 2018;138:1387–98.
122. Ingles J, Goldstein J, Thaxton C, et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. *Circ Genom Precis Med*. 2019;12:e002460.
123. Ingles J, Burns C, Funke B. Pathogenicity of hypertrophic cardiomyopathy variants: a path forward together. *Circ Cardiovasc Genet*. 2017;10:e001916.

124. Maron BJ, Roberts WC, Arad M, et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. *JAMA*. 2009;301:1253–59.
125. Desai MY, Ommen SR, McKenna WJ, et al. Imaging phenotype versus genotype in hypertrophic cardiomyopathy. *Circ Cardiovasc Imaging*. 2011;4:156–68.
126. Deleted in proof.
127. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17:405–24.
128. Ouellette AC, Mathew J, Manickaraj AK, et al. Clinical genetic testing in pediatric cardiomyopathy: is bigger better?. *Clin Genet*. 2018;93:33–40.
129. Deleted in proof.
130. Morita H, Rehm HL, Menesses A, et al. Shared genetic causes of cardiac hypertrophy in children and adults. *N Engl J Med*. 2008;358:1899–908.
131. Deleted in proof.
132. Christiaans I, Birnie E, Bonse GJ, et al. Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. *Eur Heart J*. 2011;32:1161–70.
133. Semsarian C, Ingles J, Wilde AA. Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives. *Eur Heart J*. 2015;36:1290–6.
134. Bagnall RD, Weintraub RG, Ingles J, et al. A prospective study of sudden cardiac death among children and young adults. *N Engl J Med*. 2016;374:2441–52.
135. Das KJ, Ingles J, Bagnall RD, et al. Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment. *Genet Med*. 2014;16:286–93.
136. Manrai AK, Funke BH, Rehm HL, et al. Genetic misdiagnoses and the potential for health disparities. *N Engl J Med*. 2016;375:655–65.
137. Mathew J, Zahavich L, Lafreniere-Roula M, et al. Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy. *Clin Genet*. 2018;93:310–9.
138. Ingles J, Burns C, Bagnall RD, et al. Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications. *Circ Cardiovasc Genet*. 2017;10:e001620.
139. Ingles J, Doolan A, Chiu C, et al. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. *J Med Genet*. 2005;42:e59.
140. Aronson SJ, Clark EH, Varugheese M, et al. Communicating new knowledge on previously reported genetic variants. *Genet Med*. 2012;14:713–9.
141. Deleted in proof.
142. David KL, Best RG, Brenman LM, et al. Patient re-contact after revision of genomic test results: points to consider—a statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2019;21:769–71.
143. Deignan JL, Chung WK, Kearney HM, et al. Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2019;21:1267–70.
144. Deleted in proof.
145. Gray B, Ingles J, Semsarian C. Natural history of genotype positive–phenotype negative patients with hypertrophic cardiomyopathy. *Int J Cardiol*. 2011;152:258–9.
146. Maron MS, Rowin EJ, Wessler BS, et al. Enhanced American College of Cardiology/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy. *JAMA Cardiol*. 2019;4:644–57.
147. O'Mahony C, Jichi F, Ommen SR, et al. International external validation study of the 2014 European Society of Cardiology guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM). *Circulation*. 2018;137:1015–23.
148. Elliott PM, Sharma S, Varnava A, et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 1999;33:1596–601.
149. Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. *Circulation*. 2009;119:1703–10.
150. Bos JM, Maron BJ, Ackerman MJ, et al. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. *Am J Cardiol*. 2010;106:1481–6.
151. Dimitrow PP, Chojnowska L, Rudzinski T, et al. Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-up. *Eur Heart J*. 2010;31:3084–93.
152. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. *N Engl J Med*. 2000;342:1778–85.
153. Autore C, Bernabò P, Barilla CS, et al. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. *J Am Coll Cardiol*. 2005;45:1076–80.
154. Elliott PM, Gimeno Blanes JR, Mahon NG, et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. *Lancet*. 2001;357:420–4.
155. Ichida M, Nishimura Y, Kario K. Clinical significance of left ventricular apical aneurysms in hypertrophic cardiomyopathy patients: the role of diagnostic electrocardiography. *J Cardiol*. 2014;64:265–72.
156. Wang W, Lian Z, Rowin EJ, et al. Prognostic implications of nonsustained ventricular tachycardia in high-risk patients with hypertrophic cardiomyopathy. *Circ Arrhythm Electrophysiol*. 2017;10:e004604.
157. O'Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). *Eur Heart J*. 2014;35:2010–20.
158. Binder J, Attenhofer Jost CH, Klarich KW, et al. Apical hypertrophic cardiomyopathy: prevalence and correlates of apical outpouching. *J Am Soc Echocardiogr*. 2011;24:775–81.
159. Rowin EJ, Maron BJ, Carrick RT, et al. Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction. *J Am Coll Cardiol*. 2020;75:3033–43.
160. Marstrand P, Han L, Day SM, et al. Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe registry. *Circulation*. 2020;141:1371–83.
161. O'Mahony C, Tome-Esteban M, Lambiase PD, et al. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. *Heart*. 2013;99:534–41.
162. Maron BJ, Spirito P, Shen W-K, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. *JAMA*. 2007;298:405–12.
163. Vriesendorp PA, Schinkel AF, Van Cleemput J, et al. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications. *Am Heart J*. 2013;166:496–502.
164. Maron BJ, Spirito P, Ackerman MJ, et al. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2013;61:1527–35.
165. Norrish G, Cantarutti N, Pissaridou E, et al. Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: a systematic review and meta-analysis. *Eur J Prev Cardiol*. 2017;24:1220–30.
166. Moak JP, Leifer ES, Tripodi D, et al. Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events. *Pediatr Cardiol*. 2011;32:1096–105.
167. Yetman AT, Hamilton RM, Benson LN, et al. Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 1998;32:1943–50.
168. Bharucha T, Lee KJ, Daubeney PE, et al. Sudden death in childhood cardiomyopathy: results from a long-term national population-based study. *J Am Coll Cardiol*. 2015;65:2302–10.
169. Kamp AN, Von Bergen NH, Henrikson CA, et al. Implanted defibrillators in young hypertrophic cardiomyopathy patients: a multicenter study. *Pediatr Cardiol*. 2013;34:1620–7.
170. Maron BJ, Rowin EJ, Casey SA, et al. Hypertrophic cardiomyopathy in children, adolescents, and young adults associated with low cardiovascular mortality with contemporary management strategies. *Circulation*. 2016;133:62–73.
171. Miron A, Lafreniere-Roula M, Fan CS, et al. A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. *Circulation*. 2020;142:217–29.
172. Smith BM, Dorfman AL, Yu S, et al. Clinical significance of late gadolinium enhancement in patients <20 years of age with hypertrophic cardiomyopathy. *Am J Cardiol*. 2014;113:1234–39.
173. Axelsson Raja A, Farhad H, Valente AM, et al. Prevalence and progression of late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy. *Circulation*. 2018;138:782–92.

174. Lampert R, Olshansky B, Heidbuchel H, et al. Safety of sports for athletes with implantable cardioverter-defibrillators: long-term results of a prospective multinational registry. *Circulation*. 2017;135:2310–2.
175. Providencia R, Kramer DB, Pimenta D, et al. Transvenous implantable cardioverter-defibrillator (ICD) lead performance: a meta-analysis of observational studies. *J Am Heart Assoc*. 2015;4:e002418.
176. Hauser RG, Maisel WH, Friedman PA, et al. Longevity of Sprint Fidelis implantable cardioverter-defibrillator leads and risk factors for failure: implications for patient management. *Circulation*. 2011;123:358–63.
177. Hauser RG, Maron BJ, Marine JE, et al. Safety and efficacy of transvenous high-voltage implantable cardioverter-defibrillator leads in high-risk hypertrophic cardiomyopathy patients. *Heart Rhythm*. 2008;5:1517–22.
178. O'Mahony C, Lambiase PD, Quarta G, et al. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. *Heart*. 2012;98:116–25.
179. Lambiase PD, Barr C, Theuns DA, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. *Eur Heart J*. 2014;35:1657–65.
180. Lambiase PD, Gold MR, Hood M, et al. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. *Heart Rhythm*. 2016;13:1066–74.
181. Frommeyer G, Dechering DG, Zumhagen S, et al. Long-term follow-up of subcutaneous ICD systems in patients with hypertrophic cardiomyopathy: a single-center experience. *Clin Res Cardiol*. 2016;105:89–93.
182. Weinstock J, Bader YH, Maron MS, et al. Subcutaneous implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy: an initial experience. *J Am Heart Assoc*. 2016;5:e002488.
183. Srinivasan NT, Patel KH, Qamar K, et al. Disease severity and exercise testing reduce subcutaneous implantable cardioverter-defibrillator left sternal ECG screening success in hypertrophic cardiomyopathy. *Circ Arrhythm Electrophysiol*. 2017;10:e004801.
184. Afzal MR, Evenson C, Badin A, et al. Role of exercise electrocardiogram to screen for T-wave oversensing after implantation of subcutaneous implantable cardioverter-defibrillator. *Heart Rhythm*. 2017;14:1436–9.
185. Vamos M, Healey JS, Wang J, et al. Implantable cardioverter-defibrillator therapy in hypertrophic cardiomyopathy: a SIMPLE substudy. *Heart Rhythm*. 2018;15:386–92.
186. Francia P, Adduci C, Semprini L, et al. Prognostic implications of defibrillation threshold testing in patients with hypertrophic cardiomyopathy. *J Cardiovasc Electrophysiol*. 2017;28:103–8.
187. Okamura H, Friedman PA, Inoue Y, et al. Single-coil defibrillator leads yield satisfactory defibrillation safety margin in hypertrophic cardiomyopathy. *Circ J*. 2016;80:2199–203.
188. Quin EM, Cuoco FA, Forcina MS, et al. Defibrillation thresholds in hypertrophic cardiomyopathy. *J Cardiovasc Electrophysiol*. 2011;22:569–72.
189. Friedman PA, McClelland RL, Bamlet WR, et al. Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the Detect Supraventricular Tachycardia Study. *Circulation*. 2006;113:2871–79.
190. Theuns DA, Klootwijk AP, Goedhart DM, et al. Prevention of inappropriate therapy in implantable cardioverter-defibrillators: results of a prospective, randomized study of tachyarrhythmia detection algorithms. *J Am Coll Cardiol*. 2004;44:2362–7.
191. Kolb C, Sturmer M, Sick P, et al. Reduced risk for inappropriate implantable cardioverter-defibrillator shocks with dual-chamber therapy compared with single-chamber therapy: results of the randomized OPTION study. *J Am Coll Cardiol HF*. 2014;2:611–9.
192. Peterson PN, Greenlee RT, Go AS, et al. Comparison of inappropriate shocks and other health outcomes between single- and dual-chamber implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: results from the cardiovascular research network longitudinal study of implantable cardioverter-defibrillators. *J Am Heart Assoc*. 2017;6:e006937.
193. Defaye P, Boveda S, Klug D, et al. Dual- vs. single-chamber defibrillators for primary prevention of sudden cardiac death: long-term follow-up of the defibrillateur automatique implantable-prevention primaire registry. *Eur J Echocardiogr*. 2017;19:1478–84.
194. Hu ZY, Zhang J, Xu ZT, et al. Efficiencies and complications of dual chamber versus single chamber implantable cardioverter defibrillators in secondary sudden cardiac death prevention: a meta-analysis. *Lung Cir*. 2016;25:148–54.
195. Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. *J Am Coll Cardiol*. 1997;29:435–41.
196. Kappenberger L, Linde C, Daubert C, et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. *PIC Study Group*. *Eur Heart J*. 1997;18:1249–56.
197. Maron BJ, Nishimura RA, McKenna WJ, et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). *Circulation*. 1999;99:2927–33.
198. Mickelsen S, Bathina M, Hsu P, et al. Doppler evaluation of the descending aorta in patients with hypertrophic cardiomyopathy: potential for assessing the functional significance of outflow tract gradients and for optimizing pacemaker function. *J Interv Card Electrophysiol*. 2004;11:47–53.
199. Killu AM, Park JY, Sara JD, et al. Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy. *Eur J Echocardiogr*. 2018;20:82–8.
200. Gu M, Jin H, Hua W, et al. Clinical outcome of cardiac resynchronization therapy in dilated-phase hypertrophic cardiomyopathy. *J Geriatr Cardiol*. 2017;14:238–44.
201. Rogers DP, Marazia S, Chow AW, et al. Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy. *Eur J Heart Fail*. 2008;10:507–13.
202. Rowin EJ, Mohanty S, Madias C, et al. Benefit of cardiac resynchronization therapy in end-stage nonobstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol EP*. 2019;5:131–3.
203. Cappelli F, Morini S, Pieragnoli P, et al. Cardiac resynchronization therapy for end-stage hypertrophic cardiomyopathy: the need for disease-specific criteria. *J Am Coll Cardiol*. 2018;71:464–6.
204. Cohen LS, Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. *Circulation*. 1967;35:847–51.
205. Adelman AG, Shah PM, Gramiak R, et al. Long-term propranolol therapy in muscular subaortic stenosis. *Br Heart J*. 1970;32:804–11.
206. Stenson RE, Flamm MD Jr, Harrison DC, et al. Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy. *Am J Cardiol*. 1973;31:763–73.
207. Bonow RO, Rosing DR, Bacharach SL, et al. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. *Circulation*. 1981;64:787–96.
208. Rosing DR, Kent KM, Maron BJ, et al. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. *Circulation*. 1979;60:1208–13.
209. Toshima H, Koga Y, Nagata H, et al. Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study. *Jpn Heart J*. 1986;27:701–15.
210. Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2005;45:1251–8.
211. Sherrid MV, Shetty A, Winson G, et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil. *Circ Heart Fail*. 2013;6:694–702.
212. Adler A, Fourey D, Weissler-Snir A, et al. Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients. *J Am Heart Assoc*. 2017;6:e005152.
213. Maron BJ, Dearani JA, Ommen SR, et al. Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction. *J Am Coll Cardiol*. 2015;66:1307–8.
214. Braunwald E, Ebert PA. Hemodynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs. *Am J Cardiol*. 1962;10:489–95.
215. Kirk CRGJ, Thomas R, Radley-Smith R, Qureshi SA. Cardiovascular collapse after verapamil in supraventricular tachycardia. *Arc Dis Child*. 1987;62:1265–6.
216. Teo EP, Teoh JG, Hung J. Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy. *Curr Opin Cardiol*. 2015;30:475–82.
217. Di Tommaso L, Stassano P, Mannacio V, et al. Asymmetric septal hypertrophy in patients with severe aortic stenosis: the usefulness of associated septal myectomy. *J Thorac Cardiovasc Surg*. 2013;145:171–5.
218. Kayalar N, Schaff HV, Daly RC, et al. Concomitant septal myectomy at the time of aortic valve replacement for severe aortic stenosis. *Ann Thorac Surg*. 2010;89:459–64.

219. Batzner A, Pfeiffer B, Neugebauer A, et al. Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. *J Am Coll Cardiol*. 2018;72:3087–94.
220. Nguyen A, Schaff HV, Hang D, et al. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a propensity score-matched cohort. *J Thorac Cardiovasc Surg*. 2019;157:306–315 e3.
221. Kimmelstiel C, Zisa DC, Kuttub JS, et al. Guideline-based referral for septal reduction therapy in obstructive hypertrophic cardiomyopathy is associated with excellent clinical outcomes. *Circ Cardiovasc Interv*. 2019;12:e007673.
222. Mitra A, Ghosh RK, Bandyopadhyay D, et al. Significance of pulmonary hypertension in hypertrophic cardiomyopathy. *Curr Probl Cardiol*. 2020;45:100398.
223. Ong KC, Geske JB, Hebl VB, et al. Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy. *Eur Heart J Cardiovasc Imaging*. 2016;17:604–10.
224. Desai MY, Bhonsale A, Patel P, et al. Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes. *J Am Coll Cardiol Img*. 2014;7:26–36.
225. Nguyen A, Schaff HV, Nishimura RA, et al. Determinants of reverse remodeling of the left atrium after transaortic myectomy. *Ann Thorac Surg*. 2018;106:447–53.
226. Finocchiaro G, Haddad F, Kobayashi Y, et al. Impact of septal reduction on left atrial size and diastole in hypertrophic cardiomyopathy. *Echocardiography*. 2016;33:686–94.
227. Blackshear JL, Kusumoto H, Safford RE, et al. Usefulness of von Willebrand factor activity indexes to predict therapeutic response in hypertrophic cardiomyopathy. *Am J Cardiol*. 2016;117:436–42.
228. Blackshear JL, Stark ME, Agnew RC, et al. Remission of recurrent gastrointestinal bleeding after septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy-associated acquired von Willebrand syndrome. *J Thromb Haemost*. 2015;13:191–6.
229. Desai MY, Smedira NG, Dhillion A, et al. Prediction of sudden death risk in obstructive hypertrophic cardiomyopathy: potential for refinement of current criteria. *J Thorac Cardiovasc Surg*. 2018;156:750–759 e3.
230. McLeod CJ, Ommen SR, Ackerman MJ, et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. *Eur Heart J*. 2007;28:2583–8.
231. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2017;135:e1159–95.
232. Sorajja P, Nishimura RA, Gersh BJ, et al. Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study. *J Am Coll Cardiol*. 2009;54:234–41.
233. Ball W, Ivanov J, Rakowski H, et al. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. *J Am Coll Cardiol*. 2011;58:2313–21.
234. Hodges K, Rivas CG, Aguilera J, et al. Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center. *J Thorac Cardiovasc Surg*. 2019;157:2289–99.
235. Cui H, Schaff HV, Nishimura RA, et al. Conduction abnormalities and long-term mortality following septal myectomy in patients with obstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2019;74:645–55.
236. Holst KA, Hanson KT, Ommen SR, et al. Septal myectomy in hypertrophic cardiomyopathy: national outcomes of concomitant mitral surgery. *Mayo Clin Proc*. 2019;94:66–73.
237. Hong JH, Schaff HV, Nishimura RA, et al. Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures. *J Am Coll Cardiol*. 2016;68:1497–504.
238. Bourmayan C, Razavi A, Fournier C, et al. Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echographic study. *Am Heart J*. 1985;109:1311–6.
239. Alvares RF, Goodwin JF. Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs. *Br Heart J*. 1982;48:204–12.
240. Wilmschurst PT, Thompson DS, Juul SM, et al. Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy. *Br Heart J*. 1986;56:544–53.
241. Udelson JE, Bonow RO, O’Gara PT, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. *Circulation*. 1989;79:1052–60.
242. Pacileo G, De Cristofaro M, Russo MG, et al. Hypertrophic cardiomyopathy in pediatric patients: effect of verapamil on regional and global left ventricular diastolic function. *Can J Cardiol*. 2000;16:146–52.
243. Sugihara H, Taniguchi Y, Ito K, et al. Effects of diltiazem on myocardial perfusion abnormalities during exercise in patients with hypertrophic cardiomyopathy. *Ann Nucl Med*. 1998;12:349–54.
244. Gilligan DM, Chan WL, Joshi J, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 1993;21:1672–9.
245. Spoladore R, Maron MS, D’Amato R, et al. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. *Eur Heart J*. 2012;33:1724–33.
246. Spicer RL, Rocchini AP, Crowley DC, et al. Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy. *Circulation*. 1983;67:413–20.
247. Axelsson A, Iversen K, Vejstrup N, et al. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol*. 2015;3:123–31.
248. Nguyen A, Schaff HV, Nishimura RA, et al. Apical myectomy for patients with hypertrophic cardiomyopathy and advanced heart failure. *J Thorac Cardiovasc Surg*. 2019;S0022-5223(19)30772-X.
249. Guttman OP, Rahman MS, O’Mahony C, et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. *Heart*. 2014;100:465–72.
250. Maron BJ, Olivetto I, Bellone P, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2002;39:301–7.
251. Jung H, Yang PS, Jang E, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy: a nationwide cohort study. *Chest*. 2019;155:354–63.
252. Noseworthy PA, Yao X, Shah ND, et al. Stroke and bleeding risks in NOAC- and warfarin-treated patients with hypertrophic cardiomyopathy and atrial fibrillation. *J Am Coll Cardiol*. 2016;67:3020–1.
253. Dominguez F, Climent V, Zorio E, et al. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. *Int J Cardiol*. 2017;248:232–8.
254. Mahajan R, Perera T, Elliott AD, et al. Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis. *Eur Heart J*. 2018;39:1407–15.
255. Olivetto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. *Circulation*. 2001;104:2517–24.
256. Boriani G, Glotzer TV, Santini M, et al. Device-detected atrial fibrillation and risk for stroke: an analysis of >10 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). *Eur Heart J*. 2014;35:508–16.
257. Zhao DS, Shen Y, Zhang Q, et al. Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. *Europace*. 2016;18:508–20.
258. Bassiouny M, Lindsay BD, Lever H, et al. Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy. *Heart Rhythm*. 2015;12:1438–47.
259. Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation*. 2016;133:e506–74.
260. Van Gelder IC, Healey JS, Crijns H, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. *Eur Heart J*. 2017;38:1339–44.
261. Gorenec BC, Bax J, Boriani G, et al. Device-detected subclinical atrial tachyarrhythmias: definition, implications and management—an European Heart Rhythm Association (EHRA) consensus document. *Europace*. 2017;19:1556–78.
262. Swiryn S, Orlov MV, Benditt DG, et al. Clinical implications of brief device-detected atrial tachyarrhythmias in a cardiac rhythm management device population: results from the registry of atrial tachycardia and atrial fibrillation episodes. *Circulation*. 2016;134:1130–40.

263. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. *N Engl J Med*. 2012;366:120–9.
264. Botto GL, Padeletti L, Santini M, et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. *J Cardiovasc Electrophysiol*. 2009;20:241–8.
265. Robinson K, Frenneaux MP, Stockins B, et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. *J Am Coll Cardiol*. 1990;15:1279–85.
266. Adler A, Fourey D, Weissler-Snir A, et al. Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients. *J Am Heart Assoc*. 2017;6:e005152.
267. Moore JC, Trager L, Anzia LE, et al. Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: a case series and literature review. *Pacing Clin Electrophysiol*. 2018;41:396–401.
268. Miller CAS, Maron MS, NAMr Estes, et al. Safety, side effects and relative efficacy of medications for rhythm control of atrial fibrillation in hypertrophic cardiomyopathy. *Am J Cardiol*. 2019;123:1859–62.
269. Providencia R, Elliott P, Patel K, et al. Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis. *Heart*. 2016;102:1533–43.
270. Santangeli P, Di Biase L, Themistoclakis S, et al. Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: long-term outcomes and mechanisms of arrhythmia recurrence. *Circ Arrhythm Electrophysiol*. 2013;6:1089–94.
271. Chen MS, McCarthy PM, Lever HM, et al. Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy. *Am J Cardiol*. 2004;93:373–5.
272. Bogachev-Prokophiev AV, Afanasyev AV, Zheleznev SI, et al. Concomitant ablation for atrial fibrillation during septal myectomy in patients with hypertrophic obstructive cardiomyopathy. *J Thorac Cardiovasc Surg*. 2018;155:1536–42.e2.
273. Lapenna E, Pozzoli A, De Bonis M, et al. Mid-term outcomes of concomitant surgical ablation of atrial fibrillation in patients undergoing cardiac surgery for hypertrophic cardiomyopathy. *Eur J Cardiothorac Surg*. 2017;51:1112–8.
274. Rowin EJ, Maron BJ, Kiernan MS, et al. Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplant. *Circ Heart Fail*. 2014;7:967–75.
275. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. *JAMA*. 2006;295:165–71.
276. Santangeli P, Muser D, Maeda S, et al. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: a systematic review and meta-analysis of randomized controlled trials. *Heart Rhythm*. 2016;13:1552–9.
277. Baquero GA, Banchs JE, Depalma S, et al. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies. *J Cardiovasc Electrophysiol*. 2012;23:296–301.
278. Gao D, Van Herendaal H, Alshengeiti L, et al. Mexiletine as an adjunctive therapy to amiodarone reduces the frequency of ventricular tachyarrhythmia events in patients with an implantable defibrillator. *J Cardiovasc Pharmacol*. 2013;62:199–204.
279. Link MS, Bockstall K, Weinstock J, et al. Ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy and defibrillators: triggers, treatment, and implications. *J Cardiovasc Electrophysiol*. 2017;28:531–7.
280. Wilkoff BL, et al. 2015 HRS/EHRA/APHS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. *Europace*. 2017;19:580.
281. Santangeli P, Di Biase L, Lakkireddy D, et al. Radiofrequency catheter ablation of ventricular arrhythmias in patients with hypertrophic cardiomyopathy: safety and feasibility. *Heart Rhythm*. 2010;7:1036–42.
282. Igarashi M, Nogami A, Kurosaki K, et al. Radiofrequency catheter ablation of ventricular tachycardia in patients with hypertrophic cardiomyopathy and apical aneurysm. *J Am Coll Cardiol EP*. 2018;4:339–50.
283. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;128:e240–327.
284. Hebl VB, Miranda WR, Ong KC, et al. The natural history of nonobstructive hypertrophic cardiomyopathy. *Mayo Clin Proc*. 2016;91:279–87.
285. Rowin EJ, Maron MS, Chan RH, et al. Interaction of adverse disease related pathways in hypertrophic cardiomyopathy. *Am J Cardiol*. 2017;120:2256–64.
286. Kato TS, Takayama H, Yoshizawa S, et al. Cardiac transplantation in patients with hypertrophic cardiomyopathy. *Am J Cardiol*. 2012;110:568–74.
287. Lee MS, Zimmer R, Kobashigawa J. Long-term outcomes of orthotopic heart transplantation for hypertrophic cardiomyopathy. *Transplant Proc*. 2014;46:1502–5.
288. Grupper A, Park SJ, Pereira NL, et al. Role of ventricular assist therapy for patients with heart failure and restrictive physiology: improving outcomes for a lethal disease. *J Heart Lung Transplant*. 2015;34:1042–9.
289. Muthiah K, Phan J, Robson D, et al. Centrifugal continuous-flow left ventricular assist device in patients with hypertrophic cardiomyopathy: a case series. *ASAIO J*. 2013;59:183–7.
290. Patel SR, Saeed O, Naftel D, et al. Outcomes of restrictive and hypertrophic cardiomyopathies after LVAD: an INTERMACS analysis. *J Card Fail*. 2017;23:859–67.
291. Topilsky Y, Pereira NL, Shah DK, et al. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. *Circ Heart Fail*. 2011;4:266–75.
292. Saberi S, Wheeler M, Bragg-Gresham J, et al. Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy: a randomized clinical trial. *JAMA*. 2017;317:1349–57.
293. Sweeting J, Ingles J, Ball K, et al. A control theory-based pilot intervention to increase physical activity in patients with hypertrophic cardiomyopathy. *Am J Cardiol*. 2018;122:866–71.
294. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;140:e596–646.
295. Baggish AL, Ackerman MJ, Lampert R. Competitive sport participation among athletes with heart disease: a call for a paradigm shift in decision making. *Circulation*. 2017;136:1569–71.
296. Deleted in proof.
297. Pelliccia A, Solberg EE, Papadakis M, et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). *Eur Heart J*. 2019;40:19–33.
298. Lampert R, Olshansky B, Heidebuchel H, et al. Safety of sports for athletes with implantable cardioverter-defibrillators: results of a prospective, multinational registry. *Circulation*. 2013;127:2021–30.
299. Deigaard LA, Haland TF, Lie OH, et al. Vigorous exercise in patients with hypertrophic cardiomyopathy. *Int J Cardiol*. 2018;250:157–63.
300. Pelliccia A, Lemme E, Maestrini V, et al. Does sport participation worsen the clinical course of hypertrophic cardiomyopathy? Clinical outcome of hypertrophic cardiomyopathy in athletes. *Circulation*. 2018;137:531–3.
301. Turkowski KL, Bos JM, Ackerman NC, et al. Return-to-play for athletes with genetic heart diseases. *Circulation*. 2018;137:1086–8.
302. Elliott PM, Anastakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J*. 2014;35:2733–79.
303. US Department of Transportation, Federal Aviation Administration. Medical Certification. Available at: https://www.faa.gov/licenses_certificates/medical_certification/. Accessed April 29, 2020.
304. D'Arcy JL, Manen O, Davenport ED, et al. Heart muscle disease management in aircrew. *Heart*. 2019;105:s50–6.
305. Guttmann OP, Pavlou M, O'Mahony C, et al. Prediction of thromboembolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). *Eur J Heart Fail*. 2015;17:837–45.
306. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. *Eur Heart J*. 2018;39:3165–241.
307. Pieper PG, Walker F. Pregnancy in women with hypertrophic cardiomyopathy. *Neth Heart J*. 2013;21:14–8.
308. Easter SR, Rouse CE, Duarte V, et al. Planned vaginal delivery and cardiovascular morbidity in pregnant women with heart disease. *Am J Obstet Gynecol*. 2020;222:77.e1–11.
309. Goland S, van Hagen IM, Elbaz-Greener G, et al. Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC). *Eur Heart J*. 2017;38:2683–90.

310. Thaman R, Varnava A, Hamid MS, et al. Pregnancy related complications in women with hypertrophic cardiomyopathy. *Heart*. 2003;89:752–6.
311. Billebeau G, Etienne M, Cheikh-Khelifa R, et al. Pregnancy in women with a cardiomyopathy: outcomes and predictors from a retrospective cohort. *Arch Cardiovasc Dis*. 2018;111:199–209.
312. Autore C, Conte MR, Piccinino M, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2002;40:1864–9.
313. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016;37:2893–962.
314. Canepa M, Sorensen LL, Pozios I, et al. Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy. *Am J Cardiol*. 2013;112:1182–9.
315. Olivotto I, Maron BJ, Tomberli B, et al. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2013;62:449–57.
316. Fumagalli C, Maurizi N, Day SM, et al. Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy. *JAMA Cardiol*. 2019:1–8.
317. Smith JR, Medina-Inojosa JR, Layrissa V, et al. Predictors of exercise capacity in patients with hypertrophic obstructive cardiomyopathy. *J Clin Med*. 2018;7:E447.
318. Gruner C, Ivanov J, Care M, et al. Toronto hypertrophic cardiomyopathy genotype score for prediction of a positive genotype in hypertrophic cardiomyopathy. *Circ Cardiovasc Genet*. 2013;6:19–26.
319. Claes GR, van Tienen FH, Lindsey P, et al. Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriers. *Eur Heart J*. 2016;37:1815–22.
320. Eleid MF, Konecny T, Orban M, et al. High prevalence of abnormal nocturnal oximetry in patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2009;54:1805–9.
321. Konecny T, Brady PA, Orban M, et al. Interactions between sleep disordered breathing and atrial fibrillation in patients with hypertrophic cardiomyopathy. *Am J Cardiol*. 2010;105:1597–602.
322. Konecny T, Geske JB, Ludka O, et al. Decreased exercise capacity and sleep-disordered breathing in patients with hypertrophic cardiomyopathy. *Chest*. 2015;147:1574–81.
323. Wang S, Cui H, Song C, et al. Obstructive sleep apnea is associated with nonsustained ventricular tachycardia in patients with hypertrophic obstructive cardiomyopathy. *Heart Rhythm*. 2019;16:694–701.